Louisiana State University

LSU Digital Commons
LSU Doctoral Dissertations

Graduate School

2004

Effects of gp130 cytokines on adipocytes
Sanjin Zvonic
Louisiana State University and Agricultural and Mechanical College

Follow this and additional works at: https://digitalcommons.lsu.edu/gradschool_dissertations

Recommended Citation
Zvonic, Sanjin, "Effects of gp130 cytokines on adipocytes" (2004). LSU Doctoral Dissertations. 3173.
https://digitalcommons.lsu.edu/gradschool_dissertations/3173

This Dissertation is brought to you for free and open access by the Graduate School at LSU Digital Commons. It
has been accepted for inclusion in LSU Doctoral Dissertations by an authorized graduate school editor of LSU
Digital Commons. For more information, please contactgradetd@lsu.edu.

EFFECTS OF GP130 CYTOKINES ON ADIPOCYTES

A Dissertation
Submitted to the Graduate Faculty of the
Louisiana State University and
Agricultural and Mechanical College
In partial fulfillment of the
Requirements for the degree of
Doctor of Philosophy
in
The Department of Biological Sciences

by
Sanjin Zvonić
B.S., Louisiana State University, 2000
May 2004

ACKNOWLEDGEMENTS

First and foremost I would like to thank my advisor, Dr. Jacqueline Stephens, for
the endless patience, devotion, care, guidance, trust, encouragement, sacrifice, and
support she has provided me over these four years. Thank you for having faith in me,
thank you for challenging me, thank you for helping me grow as a person. Above all,
thank you for making me realize my full potential and not settle for anything else but my
very best. Working with you has been one of the best experiences of my life, and I will
always think of you as a wonderful mentor as well as a dear friend.
I would also like to express my sincere gratitude to my graduate committee.
Thanks to Dr. Maren Hegsted for all of her help during the somewhat traumatic start of
my graduate career, as well as for her continued guidance and support. Thanks to Dr.
Richard Bruch for evoking my interest in physiology and cell signaling, and for his
constant guidance throughout these years. Thanks to Dr. Steven Smith for numerous
impromptu discussions, most of which left me scratching my head and running to the
library, and for all of his support throughout my graduate program.
Thanks to everyone in the Stephens lab for creating a challenging, productive, and
fun work environment. I would especially like to thank Dr. Beth Floyd for always being
there to lend a helping hand and give great advice. Thank you for all the insightful
discussions and for pointing out many details I often overlooked. Thanks to Pat ArbourReily for her help with mRNA analysis, and for always putting a smile on my face.
Thanks to Kyle Waite and Jeb Baugh for maintaining cell culture, taking care of ordering,
and making sure everything in the lab runs smoothly. Thanks to Jessica Hogan for

ii

helping me out whenever possible, for fighting in the trenches next to me, and for being a
great friend. I wish her the best of luck in her future endeavors and I hope all her dreams
come true.
I would also like to thank Dr. Randall Mynatt and everyone in his lab, especially
Steven Bond, for a great deal of help with the animal studies. Thanks to Dr. William
Stewart and Dr. Peter Cornelius for their collaborations with the CNTF study. Thanks to
Hollie Hale-Donze and Cindy Henk for their help with preparing my posters and
presentations.
Last, but certainly not the least, I would like to express my most sincere gratitude
and appreciation to my friends and family. Thanks to the Coleman family; Nick, Laura,
Cindy, and Ernie, for their love and support, for welcoming me into their home and their
hearts, and for letting me know I always have someone watching over me. Thanks to my
mother Anđelka, my father Senad, my brother Saša, my sister-in-law Ivana, my nephew
Alen, and the rest of my family for their life-long love, support, and devotion. Thank you
for believing in my dream and for enduring a great sacrifice to help me realize it. You
are my unfailing source of strength and inspiration, and for this I admire you and love
you with all of my being. Finally, I would like to thank Matt for our wonderful family,
for all his love and devotion, for giving me a place to belong, and for all the happiness he
has brought into my life. I could not have gone through all this without you.
I will never be able to return everything each and every one of you have given
me, but I sincerely hope that one day I will be able to make you very proud.

iii

TABLE OF CONTENTS
ACKNOWLEDGEMENTS................................................................................................ ii
LIST OF FIGURES .............................................................................................................v
ABSTRACT...................................................................................................................... vii
CHAPTER 1: INTRODUCTION
1.1 Adipocyte Research: Why and How? ..........................................................1
1.2 JAK/STAT Signaling Pathway ....................................................................6
1.3 Biology of gp130 Cytokines ......................................................................13
1.4 Ciliary Neurotrophic Factor.......................................................................19
1.5 Cardiotrophin .............................................................................................24
CHAPTER 2: EXPERIMENTAL PROCEDURES
2.1 Materials ....................................................................................................30
2.2 Cell Culture................................................................................................31
2.3 Preparation of Whole Cell Extracts ...........................................................31
2.4 Preparation of Nuclear and Cytosolic Extracts..........................................32
2.5 Gel Electrophoresis and Immunoblotting ..................................................33
2.6 RNA Analysis ............................................................................................33
2.7 Determination of [3H] 2-Deoxyglucose Uptake ........................................33
2.8 Rodent Tissue Isolation..............................................................................34
CHAPTER 3: EFFECTS OF CNTF ON ADIPOCYTES
3.1 Results........................................................................................................35
3.2 Discussion ..................................................................................................54
CHAPTER 4: EFFECTS OF CT-1 ON ADIPOCYTES
4.1 Results........................................................................................................59
4.2 Discussion ..................................................................................................68
CHAPTER 5: CROSS-TALK AMONG GP130 CYTOKINES IN ADIPOCYTES
5.1 Results........................................................................................................75
5.2 Discussion ..................................................................................................84
CHAPTER 6: SUMMARY AND CONCLUSIONS
6.1 Summary ....................................................................................................88
6.2 Conclusions................................................................................................91
LITERATURE CITED ......................................................................................................94
APPENDIX: PERMISSION TO REPRINT....................................................................122
VITA ................................................................................................................................123
iv

LIST OF FIGURES

3.1

The effects of acute CNTF or LIF treatment on 3T3-L1 preadipocytes and
adipocytes .................................................................................................................35

3.2

The expression of CNTF receptor complex proteins during adipocyte
differentiation............................................................................................................37

3.3

Tissue distribution of CNTF receptor complex components in rodents ...................38

3.4

Glycosylation of CNTF receptor complex components in rat tissues ......................39

3.5

Time and dose dependent effects of CNTF administration on the
phosphorylation and nuclear translocation of STAT proteins in 3T3-L1 cells ........41

3.6

The effects of acute CNTF administration on the expression of adipocyte
proteins......................................................................................................................44

3.7

The effects of chronic CNTF administration on the expression of adipocyte
proteins......................................................................................................................45

3.8

The expression of CNTF receptor components in the adipose tissue of lean
and obese rodents......................................................................................................47

3.9

In vivo effect of acute CNTF administration in rodents ...........................................50

3.10 In vivo expression of CNTFRα in epididymal fat pads ............................................51
3.11 CNTF does not cause insulin resistance, but increases GLUT 4 expression............52
3.12 The effects of acute CNTF treatment on IRS-1 and Akt activation in 3T3-L1
adipocytes .................................................................................................................53
4.1

The effects of acute CT-1 treatment on 3T3-L1 preadipocytes and adipocytes .......59

4.2

The effects of acute CT-1 treatment on the activation and nuclear translocation
of STAT proteins in 3T3-L1 adipocytes...................................................................60

4.3

Dose dependent effects of CT-1 on 3T3-L1 adipocytes ...........................................61

4.4

In vivo effect of acute CT-1 administration in rodents .............................................63

4.5

The effects of chronic CT-1 administration on the expression of adipocyte
proteins......................................................................................................................64

v

4.6

The effects of CT-1 and CNTF treatment on the differentiation of 3T3-L1
adipocytes .................................................................................................................66

4.7

The effects of acute CT-1 and CNTF administration on the expression of
adipocyte proteins .....................................................................................................67

5.1

gp130 cytokine administration affects cell signaling of their family members........76

5.2

CT-1 pretreatment in vivo blocks acute CT-1 signaling in rodent fat pads ..............81

5.3

Administration of LIF alters the half-life of LIFR protein in adipocytes .................82

5.4

Half-life of LIFR is altered by gp130 cytokine administration ................................83

vi

ABSTRACT

Members of the gp130 cytokine family are known for their pleiotropic roles in
various cell types. Our work has focused on their actions in adipocytes.
CNTF administration has been shown to ameliorate most complications
associated with obesity and type 2 diabetes through an unknown mechanism. In this
study CNTF is shown to activate JAK/STAT and MAPK signaling, both in vitro and in
vivo. In 3T3-L1 adipocytes, chronic CNTF also regulates the expression of SREBP-1,
FAS, IRS-1 and GLUT4. Acute CNTF administration enhances the activation of IRS-1
and Akt by insulin. Our data also demonstrate that the expression of CNTF-specific
receptor, CNTFRα, is decreased during adipocyte differentiation, but that this protein is
expressed in several other tissues, and the level of CNTFRα glycosylation varies between
different tissues. Most importantly, the expression of CNTFRα is dramatically increased
in the fat pads of obese and diabetic animals.
Even though CT-1 is mostly known for its actions in cardiomyocytes, the work
presented demonstrates that, in fat cells, CT-1 can potently induce JAK/STAT and
MAPK signaling. Neither CT-1 nor CNTF affected adipocyte differentiation, but chronic
CT-1 did induce a decrease in FAS and IRS-1 protein expression. Both CNTF and CT-1
also induced a transient increase in SOCS-3 and a transient decrease in PPARγ mRNA
levels, in a MAPK-independent manner.
Our studies also demonstrate that several gp130 cytokines, namely CT-1, LIF and
OSM, have the ability to block signaling by other gp130 cytokines, but not GH. These
cytokines can also dramatically reduce the half-life of LIFR protein in adipocytes, and
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this change in LIFR stability correlates with the ability of CT-1, LIF and OSM, to block
subsequent gp130 cytokine signaling. The loss of LIFR protein can be prevented by the
lysosome inhibitors leupeptin and chloroquine, but not by proteasome inhibitors.
In summary, these studies demonstrate than gp130 cytokines have a wide
spectrum of effects on both cultured and native adipocytes, and that their actions may be
important in various aspects of adipocyte physiology.
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CHAPTER 1: INTRODUCTION

1.1 Adipocyte Research: Why and How?
Economic growth and modernization, which occurred in nations with established
market economies over the last few decades, has in most cases lead to the adoption of a
"western" lifestyle. In such economies, the modernization of agricultural production and
food processing has lead to the dramatic increase of food availability and energy density
per capita (Seidell, 2000). Workplace mechanization and the changes in transportation
have caused an increasing percentage of population to lead very sedentary lives, and have
contributed to the alarmingly high rates of obesity and related health problems in these
nations (Seidell, 2000). According to the World Health Organization's (WHO) World
Health Report the prevalence of obesity in established market economies (Europe, USA,
Canada, etc.) is, on average, in the range of 15-20% of the total population. There is also
a growing trend of obesity among the population in the nations with developing
economies (Seidell, 2000). In the US, the prevalence overall is about 20%, with
variations within certain racial and ethnic subgroups (Flegal et al., 1998).
Obesity-related diseases, such as hypertension and type 2 diabetes (Non InsulinDependent Diabetes Mellitus, or NIDDM), are becoming a great burden, both financially
and in terms of their management and prevention (Wolf and Colditz, 1998). The WHO
estimates that by year 2025 about 300 million people will be affected by type 2 diabetes,
primarily due to obesity and related lifestyle factors (Seidell, 2000). The incidence of
type 2 diabetes is tightly linked to obesity, as 80-85% of all type 2 diabetics are also
obese (BMI > 30 kg/m2) (Must et al., 1999). At the same time, type 2 diabetes is
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characterized as a condition marked by insulin resistance in otherwise insulin-sensitive
tissues, especially skeletal muscle and adipose. Therefore, understanding the physiology
of adipose (fat) tissue, in both healthy and diseased states, is crucial for understanding the
etiology of obesity and type 2 diabetes, and for developing new strategies to combat the
world-wide epidemic of these diseases.
Until recently, adipose tissue was considered to be an inert energy depot used for
storage or release of lipid, under appropriate hormonal stimuli. However, the work
performed in the field of adipocyte biology within the last decade has revealed new
functions of adipose tissue. We now know that, apart from storing excess energy,
adipose tissue contributes to the fine tuning of energy homeostasis, and other
physiological functions (Friedman and Halaas, 1998). This is achieved through their
specific secreted gene products which include leptin, tumor necrosis factor (TNF) -α,
adiponectin, resistin, interleukin 6 (IL-6), and others (Guerre-Millo, 2002). It has also
been demonstrated that the production of these signals is regulated by feeding, fasting,
and obesity (Hamilton et al., 1995; Hotamisligil et al., 1995; Lefebvre et al., 1998).
These findings are mostly derived from the studies in white adipose tissue (WAT).
Another type of fat, the brown adipose tissue (BAT), is present in very limited quantity in
humans, while more abundant in other animals. The physiological actions of BAT
dramatically contrast that of WAT. The primary role of BAT is to dissipate energy rather
than storing it (Lowell and Flier, 1997). This is achieved through increased
mitochondrial biogenesis and the expression of uncoupling protein (UCP) -1. UCP-1
interrupts the established proton gradient of the respiratory chain across the inner
mitochondrial membrane. The result is generation of heat instead of ATP production
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(Garlid et al., 1998). Another misconception about fat tissue is that people are born with
all the adipocytes they will have as adults. However, current research clearly
demonstrates that the production of new fat cells (adipogenesis) occurs throughout the
life of the organism. Adipogenesis can be a result of normal cell turnover or the means of
producing additional fat mass for excess energy storage and weight gain (Prins and
O'Rahilly, 1997). In the former case, present adipocytes accumulate lipid until they reach
the physical limit of their size. At that point, new adipocytes are derived from their
cellular precursors, and they start accumulating the excess lipid (Miller, Jr. et al., 1984).
To study adipocyte physiology in vitro, researchers use either the immortalized,
predetermined, clonal preadipocyte cell lines, or stromovascular cells cultured from
fractionated animal fat pads. Most of the in vitro work with adipocytes utilizes the
murine 3T3-L1 and 3T3-F442A adipocyte lines. These cells were cloned from the nonclonal Swiss 3T3 cells, and, even though morphologically identical to fibroblasts, are
committed to adipocytic lineage and develop into fat cells when stimulated with
prodifferentiative agents (Green and Meuth, 1974; Green and Kehinde, 1975). Compared
to other cell lineages, the physiology of cultured fat cells in vitro exhibits very high
identity to that of fat in vivo. Cultured adipocytes closely resemble native fat cells in vivo
and express almost all adipocyte-specific genes, secrete fat-specific proteins, are insulin
sensitive, and respond to all the signals which impact fat tissue.
Cultured preadipocytes are induced to differentiate by a cocktail of hormones
(MDI) containing methyl-iso-butyl-xanthine (MIX), dexamethasone (Dex), and insulin.
Insulin and insulin-like growth factor (IGF) -1 are potent inducers of adipogenesis,
increasing the number of cells that undergo differentiation (Girard et al., 1994). They also
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increase the amount of lipid stored in each cell and have strong anti-apoptotic activity
(Kiess and Gallaher, 1998). The effects of these two factors are mediated through the
IGF-1 receptor, since preadipocytes express very limited levels of insulin receptor (Reed
and Lane, 1980). Insulin and IGF-1 induce adipogenesis mostly through activation of the
RAS/MAPK signaling pathway. Activated RAS has been shown to induce adipogenesis
in the absence of other hormonal stimuli (Benito et al., 1991). Insulin and IGF-1 also
activate protein kinase B (PKB, or Akt), which has been implicated as a possible
mediator of differentiation (Magun et al., 1996). Dexamethasone (Dex) is a synthetic
glucocorticoid hormone that activates the glucocorticoid receptor (GR). Transcriptional
targets of GR that are involved in adipogenesis are still unclear, but may involve the
proadipogenic transcription factors CCAAT/Enhancer-Binding Protein (C/EBP) –δ, and a
negative regulator of adipogenesis, preadipocyte factor (pref) -1 (Wu et al., 1996; Smas
et al., 1999; Cao et al., 1991). Methyl-iso-butyl-xanthine (MIX), a cAMP
phosphodiesterase inhibitor, results in the elevation of cAMP levels, which has
proadipogenic property (Yarwood et al., 1995). MIX-induced increase in cAMP also
leads to the expression of the proadipogenic transcription factors C/EBP-β, and CREB
(Cao et al., 1991; Reusch et al., 2000). Even though all three components of MDI are
capable of inducing adipogenesis alone, their synergistic effects, in the presence of FBS,
induce robust differentiation which results in fat cells highly similar to native adipocytes.
The addition of MDI to cultured preadipocytes leads to cell growth arrest. The
arrest is followed by 1-2 rounds of subsequent cell division known as clonal expansion.
The onset of differentiation is marked by the transient induction of proadipogenic
transcription factors C/EBP-β and δ (Darlington et al., 1998). This is followed by
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increased expression of proadipogenic transcription factors including Peroxisome
Proliferator-Activated Receptor (PPAR) –γ (Chawla et al., 1994; Tontonoz et al., 1994),
C/EBP-α (Shao and Lazar, 1997), and Signal Transducer and Activator of Transcription
(STAT) 5 (Floyd and Stephens, 2003), which can act as the central regulators of
adipogenesis. Increased transcriptional activity of these factors results in accumulation of
gene products that characterize the adipocyte phenotype: glycerolphosphate
dehydrogenase (GPDH), fatty acid synthase (FAS), acetyl CoA carboxylase (ACC),
insulin-stimulated glucose transporter GLUT4, insulin receptor, adipocyte-specific fatty
acid binding protein aP2, and many others (Spiegelman et al., 1993). Importantly, 3T3L1 adipocytes also accumulate large amounts of triglyceride, and become insulin
sensitive (Rubin et al., 1977).
Even though cultured adipocytes provide a great model for studying adipocyte
functions, they are still not completely representative of fat in vivo. Adipocytes in vivo
exist in conjunction with their extracellular matrix: stromovascular cells, preadipocytes
and nerve cells. These other cell types can effect adipocyte function. For example,
cultured fat cells produce very low levels of leptin, unlike adipocytes in vivo. Also, unlike
other tissues, WAT is located in several depots around the body (perigonadal, omental,
retroperitoneal, subcutaneous), and the behavior of mature adipocytes differs between
various depots (Ostman et al., 1979). Therefore, it is still essential to use in vivo
approaches to recapitulate the findings derived from cultured adipocytes.
Several rodent lines have been developed over the last few decades to serve as
models for studying obesity, diabetes, and general adipose physiology. Most commonly
used are ob/ob mice which do not produce leptin, db/db mice (and equivalent Zucker
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rats) which lack the leptin receptor (OBR), and several lines of agouti (AY) mice with
elevated levels of agouti protein which antagonizes the melanocortin (MC4-R) receptor
(Ingalls et al., 1996; Zhang et al., 1994; Aubert et al., 1985; Hummel et al., 1966;
Bultman et al., 1992; Gantz et al., 1993). All these animal models develop severe
obesity, type 2 diabetes, and other metabolic complications. Another strain of interest is
the inbred C57B1/6J strain. These mice are not obese on a standard diet, but become
obese on a high-fat diet, thus providing a great model for diet-induced obesity (DIO)
studies (Surwit et al., 1988). With the advances in transgenic and gene knockout
technologies, more and more animal models are being developed to mimic the possible
scenarios that may lead to the development of obesity and type 2 diabetes.
Recent statistics concerning the epidemic of obesity and type 2 diabetes are
alarming and demand immediate attention. In the light of the vast body of knowledge
already generated in the field of adipose physiology, it is obvious why further research in
this arena is crucial in developing a uniform strategy to help combat this deadly
epidemic.
1.2 JAK/STAT Signaling Pathway
Ligand binding to receptors results in a cascade of intracellular phosphorylation
events. However, most cytokine receptors possess no intrinsic kinase activity and
therefore depend on the associated cytosolic kinases to relay the signal downstream of the
ligand bound receptor. The Janus kinase (JAK) family of tyrosine kinases is a group of
proteins that can provide this activity. JAK kinases are used by several receptor families
including IL-2, IL-3, IL-10, IFN-γ, IFN-α, gp130, and single chain receptor families, as
well as some receptor tyrosine kinases (RTKs), and some G-protein-coupled receptors.
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JAK/STAT signaling is initiated when cytokine binding leads to the
conformational change in the cytoplasmic portion of its corresponding receptor. The
conformational change brings the associated JAKs in close proximity, leading to their
activation by trans-phosphorylation (Remy et al., 1999). Activated JAKs then
phosphorylate specific tyrosine residues on the receptor, making them available as
docking sites for SH2-domain containing proteins (Hubbard and Till, 2000). STATs are
a family of SH-2 domain proteins that dock on the phosphorylated receptor. Once
recruited to the receptor, they are themselves tyrosine phosphorylated by JAKs.
Phosphorylated STATs then dissociate from the receptor and dimerize. Activated STAT
dimers translocate to the nucleus, and bind specific and unique DNA elements (ISRE or
GAS elements), thus acting as transcription factors linking extracellular signaling with
gene transcription (Decker et al., 1997; Kessler et al., 1988).
The JAK family of tyrosine kinases is comprised of four members: TYK2, JAK1,
JAK2, and JAK3. JAK1, JAK2, and TYK2 are expressed ubiquitously, whereas JAK3 is
expressed exclusively in the cells of myeloid and lymphoid lineage (Krolewski et al.,
1990; Wilks et al., 1991; Harpur et al., 1992; Rane and Reddy, 1994; Kawamura et al.,
1994; Witthuhn et al., 1994). JAK1 is involved in signaling by the members of the IL-2,
IL-4, and gp130 receptor families, as well as the members of class II cytokine receptor
family (Schindler and Strehlow, 2000). Consistent with the pleiotropic use of JAK1,
JAK1 knockout animals exhibited a lethal phenotype, similar to that of LIFR knockout
animals (Rodig et al., 1998). JAK2 is used by the members of the single chain receptor
family, as well as the members of gp130 family (Schindler and Strehlow, 2000). JAK2
knockout mice have an embryonic lethal phenotype due to failure in erythropoiesis (Wu
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et al., 1995; Neubauer et al., 1998; Parganas et al., 1998). JAK3, due to its limited
expression, is used by receptors employing the common gamma chain (Schindler and
Strehlow, 2000). JAK3 knockout animals exhibit defects in lymphopoiesis, but live
normally in a pathogen free environment (Nosaka et al., 1995; Cao et al., 1995). JAK3
deficiency in humans leads to severe combined immunodeficiency (SCID) (Russell et al.,
1994). TYK2, the first identified JAK, is involved in signaling by IFNα, IL-6, IL-10, and
IL-12 (Schindler and Strehlow, 2000; Velazquez et al., 1992). Even though TYK2 null
animals have very subtle defects (Karaghiosoff et al., 2000; Shimoda et al., 2000), TYK2
seems to be important in mediating responses to IL-12 and lipopolysaccharide (LPS)
(Bogdan et al., 2000).
JAKs are constitutively associated with a proline-rich, membrane proximal,
cytosolic domain of cytokine receptors (often referred to as box 1 and box 2 regions)
(Ihle, 2001). There is also evidence that suggests that JAKs can also associate with
receptor tyrosine kinases, and some G-protein coupled receptors, enabling them to signal
via STATs (Schindler and Strehlow, 2000). Each of the JAK proteins are over 1000
amino acids long and range in size from120 to 130 kDa. Sequence analysis of JAKs
shows seven regions of high homology, termed JH1-JH7. Even though their activities
remain unclear, JH1 exhibits classical features of a kinase domain (Hubbard and Till,
2000), while JH2 represents a kinase-like (KL) pseudokinase domain (Ihle, 2001; Yeh et
al., 2000). This pseudokinase domain is a unique feature of JAK kinases (Ihle, 2001). It
has all the structural features of a tyrosine kinase, except the catalytic activity. It most
likely serves as a regulator of kinase activity, and possibly as a mediator of the
JAK/STAT interaction (Yeh et al., 2000; Velazquez et al., 1995; Flores-Morales et al.,
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1998). Domains JH3-JH7 (amino-terminal domains) are thought to be involved in
receptor association. Specifically, JH6-7 are required for JAK2 and JAK3 (Chen et al.,
1997; Kohlhuber et al., 1997), TYK2 requires additional JH elements (Yan et al., 1998),
while the entire N-terminus (including the FERM domain) is required for JAK1
association with the receptor (Kohlhuber et al., 1997).
The STAT family of proteins in mammals has seven identified members: STATs
1-4, STAT 5A and 5B, and STAT 6 (Fu et al., 1992; Zhong et al., 1994b; Akira et al.,
1994; Zhong et al., 1994a; Mui et al., 1995; Liu et al., 1995). It has been demonstrated
that the STAT family of proteins arose from the same primitive gene, evolving to
accommodate increasingly complex cell-to-cell communication needs in evolving
organisms (Aubry and Firtel, 1999; Barillas-Mury et al., 1999; Oates et al., 1999; Zeidler
et al., 2000; Pascal et al., 2001). In mammals, STATs mostly mediate host responses to
different stress circumstances (Ihle, 2001).
STAT 1 was first discovered through its involvement in signaling pathways
induced by various interferons (IFNs), and is best characterized for its actions in the
regulation of the immune system (Durbin et al., 1996; Meraz et al., 1996; Shankaran et
al., 2001). STAT 2 has been characterized along side STAT 1 for its functions in
interferon signaling. Unlike other STATs, it has not been shown to bind GAS elements
(Park et al., 1999). STAT 2 is thought to mediate not only IFN-induced signals, but also
the actions of STAT 1 in response to these signals (Park et al., 2000). To date, STAT 2 is
the least well understood of all STAT proteins. STAT 3 was first identified, and is best
known, for its involvement in the signaling of IL-6 family of cytokines (Akira et al.,
1994). More recent studies also point to its actions in cancer development (Wang et al.,
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2004), immune functions (Takeda et al., 1998; Takeda et al., 1999), acute phase response
(Alonzi et al., 2001), and skin and hair development (Sano et al., 1999). Complete
ablation of STAT 3 is embryonic lethal (Takeda et al., 1997). STAT 4 was identified in
screens for STAT homologues, but has since been shown to be important in mediating
IL-12 signaling, crucial for proper T-cell function (Kaplan et al., 1996; Thierfelder et al.,
1996). In humans, STAT 4 is also activated by type I IFNs (Rogge et al., 1998), and this
specificity is attributed to the divergence of human STAT 2 which interacts with STAT 4
(Park et al., 1999; Farrar et al., 2000). Two STAT 5 proteins, STAT 5A and STAT 5B
have very closely related sequences and are encoded by two linked genes with high
identity (Azam et al., 1995; Mui et al., 1995). Even though they were first identified as
prolactin (PRL) induced transcription factors, they have been shown to be activated by
cytokines including IL-3, IL-2, and single-chain families (Arnould et al., 1999; Asao et
al., 2001). STAT 5 proteins exhibit functional redundancy, but can have distinct
functions in the cell (Liu et al., 1997; Moriggl et al., 1996; Teglund et al., 1998;
Ormandy et al., 1997; Floyd and Stephens, 2003). STAT 6 is known for its roles in the
acquired immunity via its involvement in IL-4 and IL-13 signaling (Lin et al., 1995),
often through interaction with IRS-2 adapter protein (Ryan et al., 1996).
All STATs share several conserved structural domains. The N-terminal domain is
well conserved among the STATs. Several studies have implicated it to function in GAS
element binding, transcriptional coactivator and repressor interactions, receptor binding,
and nuclear translocation (Vinkemeier et al., 1996; Horvath, 2000; Shuai, 2000; Leung et
al., 1996; Strehlow et al., 1998). The coiled-coil domain has a helical structure that
creates large hydrophilic surfaces available for interactions with other helical proteins,
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receptor binding, tyrosine phosphorylation, and nuclear export (Horvath, 2000; Begitt et
al., 2000; Zhang et al., 2000). The DNA-binding domain has a β-barrel structure with an
immunoglobulin fold. The conformation of this domain changes with STAT activation,
and interacts with the DNA within the proximal half of the GAS element (Decker et al.,
1997; McBride et al., 2000). The linker domain connects the DNA-binding and the SH2
domains (Chen et al., 1998). It has been speculated that this allows the regulation of
DNA binding by the conformational changes in SH2 domain (following the binding of
phosphorylated tyrosine) and therefore regulates transcription (Yang et al., 1999). The
SH2 domain is the most highly conserved STAT domain. Its well conserved structure,
including a conserved arginine residue allows the SH2 domain to interact with
phosphorylated tyrosine residues (Kawata et al., 1997). This interaction is crucial for
STAT recruitment to the activated receptors, JAK association, and STAT dimerization
(Gupta et al., 1996; Darnell, 1997). The transcriptional activation (TAD) domain is not
well conserved among the STATs, consistent with its function in regulating unique
transcriptional activities (Schindler and Strehlow, 2000). Serine phosphorylation within
this region can also modulate the transcriptional activity of some genes (Decker and
Kovarik, 2000).
JAK/STAT signaling mediates numerous important physiological functions.
Thus, it is not surprising to find several regulatory mechanisms whose function is to
modulate the rate of STAT signal transduction. Negative regulation of STAT signaling is
achieved at several points in the signal cascade, including activated receptor endocytosis
(Dittrich et al., 1996), targeted degradation of both JAKs and STAT by the ubiquitinproteaseome system (Haspel et al., 1996; Callus and Mathey-Prevot, 2000), and
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dephosphorylation of JAKs by SH2 domain-containing tyrosine phosphatases such as
SHP1 and SHP2 (Yi et al., 1993). Generation of carboxy-terminally truncated STAT
isoforms (at RNA or protein level) generates proteins with dominant-negative function
that successfully attenuate STAT activity (Caldenhoven et al., 1996). STAT methylation
may also play a role in the regulation of signaling (Mowen et al., 2001). Activation of
JAK/STAT signaling pathways also leads to the initiation of negative feedback loops.
Suppressors of cytokine signaling (SOCS) are a group of proteins whose expression is
induced in this manner. Members of this family include CIS and SOCS-1, -2, and -3 .
They inhibit STAT signaling by blocking the STAT recruitment to the activated receptor
(CIS), impairing STAT interaction with JAK (SOCS-1), or via other, not yet elucidated
mechanisms (Yoshimura et al., 1995; Yasukawa et al., 1999). Another group of STATinteracting proteins are the PIAS (Protein Inhibitor of Activated STATs) proteins. They
bind activated STAT dimers in the nucleus, thus interfering with, or blocking their ability
to successfully bind DNA (Liao et al., 2000; Chung et al., 1997). STAT signaling can
also be enhanced. Serine phosphorylation of STATs has been shown to enhance their
transcriptional activity (Decker and Kovarik, 2000; Wen et al., 1995), and affect stability
(Beuvink et al., 2000). Most importantly, STAT dimers have been shown to interact with
other proteins/transcription factors, and these interactions can serve to enhance their
transcriptional activity. Some of these proteins include the glucocorticoid receptor
(Aittomaki et al., 2000), C/EBPβ (Wyszomierski and Rosen, 2001), c-Jun (Zhang et al.,
1999), NF-κB (Wang et al., 2003), as well as chromatin modifying proteins (CBP/p300,
YY1, BRAC1) (Bhattacharya et al., 1996), and various cytosolic proteins (STAM,
WD40, SH2-B) (Kim et al., 2001).
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Recent work in the field of JAK/STAT signaling has led to many important
discoveries, while also leaving many new questions for further investigation. Adipocytes
in vivo and in vitro express JAKs 1 and 2, TYK2, and STATs 1,3, 5A, 5B, and 6
(Stephens et al., 1996). Adipose STATs are activated in highly specific patterns by
different agonists, and these activations lead to very specific transcriptional effects
(Balhoff and Stephens, 1998). Therefore, studying JAK/STAT pathway in adipocytes is
a systematic approach to further elucidate the intricacy of fat physiology, especially in
response to altered metabolic states of the organism.
1.3 Biology of gp130 Cytokines
The interleukin 6 (IL-6) cytokine family, a member of the cytokine superfamily,
is a group of functionally and structurally related proteins including IL-6, IL-11,
leukemia inhibitory factor (LIF), oncostatin M (OSM), Ciliary Neurotrophic Factor
(CNTF) and cardiotrophin-1 (CT-1) (Hirano et al., 1994; Mackiewicz et al., 1995). All
these cytokines possess a similar helical structure and signal via structurally related
receptors (Bazan, 1990a; Bazan, 1990b; Taga, 1996; Pennica et al., 1996c; Kishimoto et
al., 1995). All of the IL-6 family cytokines were originally identified as factors with
distinct and unique properties: immunoglobulin production in activated B cells for IL-6
(Lee et al., 1988), growth promotion of myeloma and plasmacytoma for IL-11 (Paul et
al., 1990), growth inhibition of myeloid leukemia cells for LIF (Gearing et al., 1987),
growth inhibition of melanoma cells for OSM (Zarling et al., 1986), promotion of ciliary
neuron survival for CNTF (Stockli et al., 1989; Lin et al., 1989), and induction of cardiac
hypertrophy for CT-1 (Pennica et al., 1995a). However, we now know these cytokines
can function in a pleiotropic and redundant manner (Paul, 1989; Kishimoto et al., 1992).
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In fact, members of the IL-6 cytokine family play pivotal roles in the immune,
hemotopoietic, nervous, cardiovascular, and endocrine systems, as well as in bone
metabolism, inflammation, and acute phase responses (Sehgal et al., 1988; Hirano, 1998;
Metcalf, 1991; Patterson and Nawa, 1993; Pennica et al., 1996c; Kishimoto et al., 1995;
Hirano, 1992; Hilton, 1992; Yang, 1993; Ip and Yancopoulos, 1996; Gearing, 1993).
Molecular cloning and structural analyses of the receptors for the cytokine
superfamily proteins have established two distinct and distantly related cytokine receptor
families. IL-6 family cytokine receptors belong to the class I cytokine receptor family
(Taga and Kishimoto, 1990; Bazan, 1990b; Taga and Kishimoto, 1992; Miyajima et al.,
1992). Members of this receptor family share a common domain of approximately 200
amino acid residues. Within this domain are four positionally conserved cysteine residues
(near the amino-terminal) and a WSXWS motif in the carboxy-terminal (Bazan, 1990b).
The domain itself is comprised of two fibronectin type III modules which are essential for
ligand binding because they form a barrel-shaped ligand binding pocket (Yawata et al.,
1993; Patthy, 1990). Aside from the IL-6 family cytokine receptors, the members of this
family include glycoprotein 130 (gp130), leptin receptor (OBR), and other similar
proteins such as G-CSFR and IL-12R (Fukunaga et al., 1990a; Fukunaga et al., 1990b;
Tartaglia et al., 1995; Lee et al., 1996; Chen et al., 1996; Chua et al., 1994; Chua et al.,
1995). Class I cytokine receptors are of great interest due to the findings that their
functional receptor forms are actually comprised of multiple membrane proteins, and that
these receptor complexes share common signal transducing subunits (Miyajima et al.,
1992; Taniguchi and Minami, 1993; Kishimoto et al., 1994). This shared usage of signal
transducers in part explains the functional redundancy of cytokines.
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Functional receptor complexes for the IL-6 cytokine family members all share
gp130 as a component required for both ligand binding and signal transduction (Taga,
1996; Pennica et al., 1996c; Wollert et al., 1996; Taga et al., 1992). Hence, IL-6 family
cytokines are often referred to as gp130 cytokines. Molecular cloning of gp130 cDNA
has demonstrated the receptor to be comprised of six fibronectin type III modules, two of
which show features typical of the class I cytokine receptor family (Hibi et al., 1990).
Several gp130 cytokines (LIF, OSM, CNTF, CT-1) also require gp130-related protein
LIFR (LIF receptor) as a part of their functional receptor complexes (Gearing et al.,
1991; Gearing et al., 1992; Ip et al., 1992; Davis et al., 1993b; Pennica et al., 1995b). In
fact, most of them have very low affinity to gp130 until it becomes a part of the
LIFR/gp130 heterodimer.
Apart from the shared functional receptor components, IL-6, IL-11, OSM, and
CNTF also have cytokine-specific receptors, often referred to as the α-receptors
(Murakami et al., 1993; Yin et al., 1993; Hilton et al., 1994). IL-6 first binds to its αreceptor, IL-6R, and then two of these IL-6/IL-6R complexes associate with gp130 each,
allowing the formation of a gp130 homodimer (Ward et al., 1994; Paonessa et al., 1995).
A similar pattern has also been proposed for the formation of IL-11 functional receptor
complex (Yin et al., 1993). OSM can either signal through the LIFR/gp130 heterodimer
(Gearing et al., 1992; Liu et al., 1992), or through its α-receptor OSMR associated with a
gp130 subunit (Thoma et al., 1994; Murakami-Mori et al., 1995). Structurally, OSMR is
closely related to both LIFR and gp130. However, neither OSMR nor LIFR can bind
OSM in the absence of gp130 subunit. The α-receptor for CNTF, CNTFRα, is
structurally closely related to extracellular region of IL-6R, but is anchored to the cell
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membrane via a glycosyl-phosphatidyl-inositol (GPI) linkage. CNTF binds to CNTFRα,
followed by the recruitment of gp130 and LIFR (Ip et al., 1992; Davis et al., 1993b).
This complex is actually hexameric, containing two CNTF and two CNTFRα proteins
along with a LIFR/gp130 heterodimer (De Serio et al., 1995).
The α-receptors for IL-6, IL-11, and CNTF can also be found in a soluble form,
and these soluble receptors can bind their ligands, just like their membrane-associated
forms (Baumann et al., 1996b; Taga et al., 1989). Soluble receptors for IL-6 are found
circulating the in serum, while the ones for CNTF are found in cerebrospinal fluid and are
released from skeletal muscle in response to peripheral nerve injury. This gives them the
potential to confer cytokine responsiveness to cells expressing gp130 and LIFR that do
not express membrane-associated forms of the receptor (Hibi et al., 1990; Davis et al.,
1993a). Interestingly, the combination of IL-6 and soluble IL-6R (sIL-6R) can mimic not
only the actions of IL-6, but also the actions of all other gp130 cytokines, on the cells
expressing gp130. This is evident from the IL-6/sIL-6R ability to promote
pluriopotentiality of ES cells, induce osteoclast formation in osteoblast/osteoclast
progenitor cocultures, or cardiomyocyte hypertrophy (Yoshida et al., 1994; Wolf et al.,
1994; Pennica et al., 1995a; Hirota et al., 1995; Tamura et al., 1993). These functions are
normally observed with LIF, OSM, and CNTF in the ES cells, LIF, OSM , and IL-11 in
osteoclast progenitor cells, or CT-1 in cardiomyocytes.
Functionally, it is the formation of the gp130/gp130 homodimer or the
LIFR/gp130 heterodimer that is essential for the downstream signal transduction of
gp130 cytokines. The function of the α-receptor is to recruit the ligand and aid in the
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formation of signal-transducing dimers in response to the ligands that are themselves
incapable of doing so.
The ubiquitous expression of gp130 in every cell type examined explains the
pleiotropic nature of gp130 cytokine action, while shared usage of gp130 by all these
cytokines in part explains the redundancy of their actions. Unlike gp130, LIFR and the
specific α-receptors exhibit a more tissue-specific expression (Saito et al., 1992) and
therefore contribute to the specificity of gp130 cytokine actions. Spatial and temporal
expression of the individual cytokines is another factor that contributes to the specificity
of their actions. For instance, following the hypoglossal nerve injury, IL-6 becomes
expressed in neighboring Schwann cells, while IL-6R becomes detectable in the nerve
cell body (Hirota et al., 1996).
Animals lacking IL-6, LIF, or CNTF do not exhibit the phenotypic abnormalities
expected with the ablation of cytokines with such pleiotropic actions, probably due to the
compensatory effects of other family members (Kopf et al., 1994; Stewart et al., 1992;
Masu et al., 1993). However, some complications developing later in life were observed.
Moreover, complete ablation of gp130 or LIFR is lethal (Yoshida et al., 1996; Ware et
al., 1995). Mice lacking gp130 die during development, 12 days postcoitum, while LIFR
deficient animals die within a day of birth. Histological examinations also reveal that
these animals suffered from hypoplastic myocardium, severely decreased hemotopoietic
cell numbers, loss of neurons, and other abnormalities, giving insight into the in vivo
functions of gp130 and LIFR.
Following stimulation by gp130 cytokines, target cells undergo a wide variety of
fates: growth promotion, growth arrest, differentiation, or the expression of specific
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genes. The specificity of cytokine actions in a given cell type arises not only from the
differences in the receptor and cytokine expression, but also from the differences in
downstream signaling pathways activated by the cytokine.
Upon stimulation by gp130 cytokines, gp130 receptor itself undergoes homo- or
heterodimerization governed by the phosphorylated tyrosine residues on the cytoplasmic
region of the protein. This dimerization triggers the activation of cytoplasmic protein
kinases associated with gp130 receptor. In the case of gp130, those kinases are JAK1,
JAK2, and TYK2 (Ihle and Kerr, 1995; Darnell et al., 1994; Lutticken et al., 1994; Stahl
et al., 1994; Stahl et al., 1995; Narazaki et al., 1994). Activated JAKs phosphorylate
tyrosine residues in the distal part of gp130 and LIFR, and provide docking sites for SH2
domain-containing proteins such as STATs (Ihle, 1996). Even though the STAT family
consists of 7 members, it is generally recognized that gp130 cytokines activate STAT 3
and, to a lesser extent, STAT 1 (Akira et al., 1994; Zhong et al., 1994b). Once recruited
to the receptor, STATs can now initiate the JAK/STAT pathway, ultimately ending up in
the nucleus, where STAT dimers bind DNA and modulate transcription.
Stimulation by gp130 cytokines can also lead to the activation of RAS/MAPK
pathway (Satoh et al., 1992). In this case, phosphorylated tyrosine residues on gp130
serve as docking sites for SH2 domain-containing adapter protein Shc, which is then
phosphorylated by JAKs (Kumar et al., 1994). Shc then forms a complex with Grb2 and
SOS that is capable of activating RAS (Gurney et al., 1995). The activation of RAS
leads to phosphorylation and activation of the Raf/ Mek/ ERK MAPK cascade, and its
downstream effectors (Boulton et al., 1994; Daeipour et al., 1993).
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1.4 Ciliary Neurotrophic Factor
Ciliary Neurotrophic Factor (CNTF) is a naturally occurring protein with a
molecular mass of approximately 22 kDa. It was originally characterized as a trophic
factor that supports the survival of embryonic chick ciliary ganglion neurons in vitro
(Adler et al., 1979; Lin et al., 1989). However, subsequent cloning and sequencing of
CNTF revealed that it is unrelated to neurotrophins, but is rather a member of the IL-6
cytokine family including IL-6, IL-11, LIF, OSM and CT-1 (Kishimoto et al., 1994; Stahl
and Yancopoulos, 1994; Pennica et al., 1995b). Its amino acid sequence reveals it is a
cytosolic protein with no signal peptide, and only one free cysteine residue (Sendtner et
al., 1992; Rende et al., 1992; Friedman et al., 1992; Sleeman et al., 2000). Mammalian
CNTF lacks a N-terminal secretion sequence and is thus not secreted. Instead, it is
considered to be a lesion factor because it is known to be released from the ruptured glial
cells to restore neuronal function following injury (Adler, 1993). CNTF shows a very
low sequence similarity to other known proteins, including related cytokines. LIF, one of
the most similar cytokines to CNTF, is only 15% homologous, while different
mammalian CNTF proteins share about 80% homology with one another (McDonald et
al., 1995; Stockli et al., 1989; Masiakowski et al., 1991; Negro et al., 1991). Chicken
CNTF, also known as GPA, shares only about 50% homology with mammalian CNTF,
and is known to be secreted (Leung et al., 1992; Reiness et al., 2001). As a member of
the IL-6 cytokine family, CNTF was predicted to have a four α-helix bundle topology
similar to that of GH, G-CSF, PRL, and EPO, as well as that of other IL-6 family
cytokines. This notion was proven to be true once the tertiary structure of CNTF had
been solved by x-ray crystallography (McDonald et al., 1995) and NMR (Panayotatos et
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al., 1995). Structurally, CNTF consists of four anti-parallel α-helices (A, B, C, D)
connected by two cross-over loops between A-B and C-D, and one short loop between BC (Kallen et al., 1999). This structure confers both stability and receptor-binding
specificity onto the CNTF molecule. Specifically, the residues R25 and R28 in helix A,
Q63 and W64 in the A-B loop, Q74 in helix B, and D175 and R177 in helix D, have been
shown to form an epitope for the CNTF-receptor recognition (Panayotatos et al., 1995;
Inoue et al., 1995). Under physiological conditions, 40µM or below, CNTF is believed to
exist in a monomeric form, but it does dimerize at concentrations above 40µM, and its
crystal structure reveals a dimer (McDonald et al., 1995). Most cytokines function as
dimers or trimers in vivo. Residue A177 is believed to be important for the cytokine
dimer formation, because the A117R CNTF mutant does not form dimers at any
concentration (Panayotatos et al., 1995).
CNTF-specific receptor, CNTFRα, has been molecularly cloned as a 75 kDa
protein, showing homology with the IL-6R (Davis et al., 1991). Upon translation, the Cterminus of CNTFRα is cleaved. This region contains hydrophobic residues found in
other transmembrane proteins. Hence, CNTFRα has no transmembrane or cytosolic
domains and is found only on the outer surface of the cell membrane. CNTFRα is
attached to the membrane by a GPI linkage, sensitive to PI-PLC treatment (Davis et al.,
1991). It has been demonstrated that new protein synthesis is required to restore CNTF
signaling upon the removal of CNTFRα by PI-PLC (Huber et al., 1993). Initially
CNTFRα has been described as being distributed predominantly within neural tissues
(Davis et al., 1991), but has since been reported in skeletal muscle, adrenal gland, sciatic
nerve, skin, kidney, and testes (Ip et al., 1992). CNTFRα cleaved from the cell surface
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can exist and act in a soluble form. The soluble CNTFRα has been detected in the serum
and the cerebrospinal fluid, and has been shown to initiate signaling in cells not
responsive to CNTF alone (Davis et al., 1993a; Helgren et al., 1994). Few mutagenesis
studies have also shown that mice lacking CNTF develop normally and appear to have no
visible defects well into adulthood, when they develop minor loss of motor neurons
(Masu et al., 1993). However, mice lacking CNTFRα tend to have severe motor neuron
defects and die perinatally because they fail to initiate feeding behaviors (DeChiara et al.,
1995). These rsults imply that CNTFRα plays an important role in the development of
the nervous system, not only as a receptor for CNTF, but also as a receptor for another
unknown CNTF-like factor. The finding that CNTF expression is undetectable in the
feeding-relevant brain sites that express high levels of CNTFRα further supports this
notion (Gloaguen et al., 1997).
CNTF signaling is initiated when CNTF binds CNTFRα, either in its soluble or
membrane-bound form (Stahl and Yancopoulos, 1994). Once a CNTF/CNTFRα
complex is formed, two of these heterodimers come together and recruit gp130
transducer protein, followed by a subsequent recruitment of LIFR protein. The resulting
receptor complex is a hexamer of CNTF, CNTFRα, gp130, and LIFR in a 2:2:1:1 ratio,
respectively (De Serio et al., 1995). Within this complex, CNTF and CNTFRα make
direct contacts with all the complex components (Davis et al., 1991). Mutagenesis data
from several sources now suggest specific sites and residues on CNTF involved in
receptor complex interactions (Savino et al., 1994; Inoue et al., 1995; Bazan, 1991).
Binding to CNTF also induces the formation of disulfide links between gp130 and LIFR
within the complex. Aside from this hexameric, high-affinity binding complex, CNTF
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can bind its receptors in a low-affinity manner (Huber et al., 1993). CNTF/CNTFRα is
considered to be a low-affinity binding complex until further bound to gp130 and LIFR.
This is especially evident in cases where CNTF can induce signaling in the absence of
CNTFRα, solely by binding of the gp130/LIFR dimeric receptor (Gearing et al., 1994;
Monville et al., 2001). Once the CNTF receptor complex is fully assembled and the
signal is propagated, all the components of the receptor complex are believed to be
endocytosed into a non-recycling intracellular pool (Alderson et al., 1999).
Unlike CNTFRα, both gp130 and LIFR contain membrane-spanning hydrophobic
domain and a cytosolic domain (Stahl and Yancopoulos, 1994). Upon receptor complex
assembly, gp130/LIFR dimerization occurs, leading to the activation of the associated
JAKs. JAK 1, JAK 2, and JAK 3 kinases have been shown to be pre-associated with
gp130/LIFR within the CNTF receptor complex. The activation of JAKs leads to the
subsequent phosphorylation of the tyrosine residues on gp130 and LIFR, which can now
act as docking sites for SH2 domain-containing proteins. Once these proteins dock, they
themselves are phosphorylated by the JAKs and are capable of propagating the signal
(Stahl et al., 1994). The STAT family of transcription factors, primarily STAT 3 and, to
a lesser degree, STAT 1, are the main targets of JAKs following CNTF activation (Bonni
et al., 1993). STAT 3 is phosphorylated at residue Y705, while STAT 1 is
phosphorylated at Y701. Activated STAT proteins then form homo or hetero dimers and
subsequently translocate to the nucleus (Bonni et al., 1993; Wegenka et al., 1993), where
they initiate transcription of genes such as c-fos (Halvorsen et al., 1996; Larkfors et al.,
1994) and tis-11 (Ip et al., 1992). Also, specific members of the SOCS protein family,
especially SOCS-3, are induced in response to CNTF (Bjorbaek et al., 1999). The
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RAS/MAPK pathway can also be engaged by CNTF via Shc, Grb2, Raf, and Mek
cascade (Boulton et al., 1994; Kumar et al., 1994). Shc is a SH2 domain-containing
adapter protein that can dock on the phosphorylated gp130 within the receptor complex
(Inoue et al., 1995). Apart from the JAK/STAT and RAS/MAPK pathways, CNTF can
lead to the activation of PLCγ and PI3K-p110 via direct associations with LIFR and
indirect associations with gp130 (Bjorbaek et al., 1999). PTP-1D, and pp120 src
substrate, can also be activated via the CNTF receptor complex (Bonni et al., 1993;
Boulton et al., 1994).
As previously mentioned, CNTF was first identified as a trophic factor for the
motor neurons in the ciliary ganglion, and was later found to act on other motor neuron
populations (Sendtner et al., 1991). Thus, it was readily evaluated as a therapeutical tool
in patients suffering from motor neuron diseases such as amyotrophic lateral sclerosis
(Miller et al., 1996). However, during these trials, CNTF administration resulted in
unexpected weight loss (ALS CNTF Treatment Study Group, 1996). This finding
implied that CNTF might act in a manner similar to cachectic cytokines, but subsequent
studies showed that it is more likely to act via a leptin-like mechanism. Cloning of the
leptin receptor OBR showed that it was closely related to the components of the CNTF
receptor complex (Davis et al., 1993b). Further studies showed that, like leptin, CNTF
can activate same signaling molecules, and that CNTFRα is co-localized with OBR in the
hypothalamic nuclei involved in feeding (Baumann et al., 1996a; Carpenter et al., 1998;
Ghilardi et al., 1996; Vaisse et al., 1996). Even though it is not secreted, CNTF can
readily cross the blood-brain barrier in a manner similar to leptin (Pan et al., 1999).
CNTF treatment of leptin-deficient ob/ob mice was found to reduce adiposity,
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hyperphagia, and hyperinsulinemia associated with this genotype. Leptin administration
has the same effect in these animals. However, unlike leptin, CNTF also corrected
obesity-related phenotypes in leptin-resistant, OBR-deficient, db/db mice, and in DIO
mice partially resistant to leptin (Gloaguen et al., 1997; Lambert et al., 2001). CNTF and
its synthetic analog Axokine® have also been found to suppress NPY gene expression
(Xu et al., 1998), and pCREB in the feeding-relevant brain sites (Lambert et al., 2001).
The weight loss caused by CNTF administration is due to the preferential loss of fat
(Henderson et al., 1996). It is believed to occur by resetting the hypothalamic weight set
point, such that cessation of CNTF treatment does not result in overeating and rebound
weight gain (Lambert et al., 2001). Unlike cachectic cytokines, the appetite diminution
during CNTF treatment is not due to stress, inflammatory responses, nausea, or
conditioned taste aversion, but rather due to the modification of NPYergic signaling
(Lambert et al., 2001; Pu et al., 2000). This is obvious when we consider that central
infusions of NPY can completely reverse weight-reducing effects of CNTF (Pu et al.,
2000).
Considering its potency and specificity in all experimental forms of obesity, it is
clear why CNTF, as well as other gp130 cytokines, should be further investigated as an
effective treatment for obesity and type 2 diabetes.
1.5 Cardiotrophin
Cardiotrophin (CT-1) was first identified in a screen of a cDNA library derived
from the mouse embryoid bodies that had previously been shown to display spontaneous
contractile activity and express cardiac-specific gene markers (Pennica et al., 1995a).
Conditioned media from these bodies has been shown to support in vitro cardiomyocyte
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survival and hypertrophy. CT-1 is a naturally occurring protein, 200 amino acids long,
with a molecular mass of approximately 21.5 kDa (Pennica et al., 1996b). Rat and
human CT-1 sequences display 94% and 79% amino acid homology with the murine CT1, respectively (Ishikawa et al., 1996). Further sequence analyses and structural
considerations have shown that CT-1 is a member of the IL-6 cytokine family (Pennica et
al., 1995a). The members of this family do not share a great deal of primary amino acid
sequence homology (14-24%) (Rose and Bruce, 1991), but they do share a common four
α-helix bundle topology (Robinson et al., 1994) and utilize gp130 signal transducer
protein in their receptor complexes (Kishimoto et al., 1995).
CT-1 lacks the conventional hydrophobic amino terminal secretion sequence, but
is found in the media of transfected cells. The coding regions of human and murine CT-1
are contained on three separate exons spanning 6-7 kbp of genomic DNA. Human CT-1
was localized to chromosome 16p11.1 p11.2. (Pennica et al., 1996b). CT-1 mRNA
expression has been detected at high levels in the heart, skeletal muscle, prostate, ovaries,
and liver, as well as fetal heart, lung, and kidney. Lower amounts were detected in the
thymus, small intestine, lung, kidney, pancreas, testes and the brain, while no expression
was found in the spleen (Pennica et al., 1995a). Both functional and receptor binding
studies in cultured cardiomyocytes have shown that CT-1 signals through the
gp130/LIFR heterodimer without the further requirement for the α-subunit. (Wollert et
al., 1996; Pennica et al., 1995b; Pennica et al., 1996a) However, CT-1 signaling in
neuronal cells may require an additional α-subunit. Cross-linking of iodinated CT-1 to
the cell surface of neuronal cell lines has identified this α-subunit as an 80 kDa (45 kDa
after N-linked deglycosylation) protein present in the receptor complexes along side
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gp130 and LIFR (Wollert et al., 1996; Robledo et al., 1997). These studies have also
shown that CT-1 binds the LIFR with the equivalent affinity as LIF, but fails to bind
gp130 alone. However, the addition of gp130 enhances its binding to LIFR. From these
observations, it has been deduced that CT-1 initially binds LIFR with a low affinity,
followed by the recruitment of gp130 into a high affinity binding complex (Pennica et al.,
1995b). The formation of gp130/LIFR complex triggers the activation and auto/transphosphorylation of receptor associated JAK1, JAK2, and TYK2 kinases (Narazaki et al.,
1994; Lutticken et al., 1994; Stahl et al., 1994), as well as other non-receptor tyrosine
kinases (Hck, Btk, Tec, Fes) (Ernst et al., 1994; Matsuda et al., 1995b; Matsuda et al.,
1995a), and SH-2 domain signaling molecules (Zhong et al., 1994b; Guschin et al., 1995;
Gerhartz et al., 1996) resulting in the subsequent activation of associated signaling
pathways. The pattern of kinase activation appears to be cell type specific (Stahl et al.,
1994).
The activation of JAK family kinases leads to the phosphorylation of the receptor
subunits, which can then recruit STAT 1 and STAT 3, leading to their phosphorylation
and nuclear translocation. There, the STAT dimers bind the cognate DNA response
elements. Phosphorylated receptor subunits can also recruit SH-2 domain adapter Shc,
leading to the complex formation with Grb2 and SOS (Kumar et al., 1994). This complex
can then activate p21ras, leading to the subsequent, cell type specific, activation of raf-1,
Mek, and ERK 1/2 MAP kinases (Nakafuku et al., 1992; Boulton et al., 1994).
As previously noted CT-1 was first identified as a factor promoting cardiac
myocyte hypertrophy in vitro with activity at concentrations (0.1 nM) much lower than
other IL-6 family cytokines. Later studies have revealed that this type of hypertrophy is
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distinct from that induced by α-adrenergic stimulation in both cell morphology and gene
expression pattern. Namely, the increase in cell size is caused by an increase in length,
not width, while the sarcomeric unit assembly occurs in series rather than in parallel
(Wollert et al., 1996). CT-1 hypertrophy also results in the increased atrial natriuretic
peptide (ANP) but, unlike α-adrenergic stimulation, it does not induce skeletal α-actin
and myosin light chain-2 synthesis. This type of hypertrophy is closely related to the
volume-overload hypertrophy during cardiac valve insufficiency.
Similarly, an in vivo chronic administration of CT-1 to rodents resulted in a dose
dependent increases in both heart weight and ventricular weight, while the total body
weight was unaffected (Jin et al., 1996). These results mimicked those of chronic in vivo
stimulation of gp130 receptor (Hirota et al., 1995). Thus, CT-1 probably plays a role in
cardiac development ensuring that the myocardium develops to the correct thickness
(Yoshida et al., 1996). It has been suggested that this function of CT-1 is governed
through its activation of the JAK/STAT pathway (Sheng et al., 1997).
Apart from its hypertrophic effects, CT-1 also has a cardioprotective effect in
cardiomyocytes. CT-1 can enhance the survival of neonatal myocytes in serum free
medium, as well as protect the cells against heat shock and simulated ischemia/hypoxia
(Sheng et al., 1996; Stephanou et al., 1998). This effect was associated with the ability of
CT-1 to induce the activation of C/EBPβ via the MAPK pathway, leading to the
increased levels of hsp70 and hsp90, and increased phosphorylation of hsp27 (Heads et
al., 1994; Heads et al., 1995; Cumming et al., 1996). Another aspect of the
cardioprotective effect is that CT-1 minimizes the degree of apoptosis (Stephanou et al.,
1998). This aspect of its function is currently under investigation.
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Other functions of CT-1 have recently been elucidated. CT-1 was shown to
elevate cardiac output and heart rate, while lowering mean arterial pressure and systemic
vascular resistance (Jin et al., 1996). It has also been shown to reduce the expression of
TNF-α in LPS treated animals (Benigni et al., 1996). Elevated TNF-α levels are
correlated with myocardial infarction and chronic heart failure (Latini et al., 1994). Like
other IL-6 cytokine family members, CT-1 can induce liver acute phase response (Peters
et al., 1995). In vivo administration of CT-1 has also resulted in hypertrophy of the liver,
kidneys, and spleen whilst causing atrophy of the thymus and increasing platelet and red
blood cell counts (Jin et al., 1996).
Similarly to induction of ANP, CT-1 also induces the expression of the brain
natriuretic peptide (BNP) (Kuwahara et al., 1998). CT-1 has also been shown to induce a
switch in the transmitter phenotype of cultured sympathetic neurons to a cholinergic
phenotype (Habecker et al., 1995). Most interestingly, CT-1 supports the long-term
survival of spinal motor neurons, as well as dopaminergic neurons lost in Parkinson's
disease, and ciliary ganglion neurons (Pennica et al., 1995b). CNTF can only mimic the
effect on ciliary ganglions. However, all of these functions require the presence of the 80
kDa receptor subunit (Robledo et al., 1997).
Because of its ability to potently activate JAK/STAT pathway through the
gp130/LIFR dimer, CT-1 can potentially affect adipocytes. Hence, these could possibly
prove important in adipose function and metabolic regulation. Recently, it has been
shown that the circulating levels of CT-1 are increased in the serum of patients with
ischemic heart disease and valvular heart disease (Freed et al., 2003). Since the onset of
cardiovascular disease (CVD) is associated with obesity/type 2 diabetes (Sowers and
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Frohlich, 2004; Reaven et al., 2004), the actions of CT-1 in fat may prove to be a link
between the clinical aspects of these two deadly diseases, and should therefore be
extensively studied.
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CHAPTER 2: EXPERIMENTAL PROCEDURES

2.1 Materials
Dulbecco's Modified Eagle's Media (DMEM) was purchased from Life
Technologies. Bovine and fetal bovine (FBS) sera were purchased from Sigma and
Invitrogen, respectively. Rat recombinant CNTF and human recombinant CT-1 were
purchased from Calbiochem. Recombinant mouse IL-6 and recombinant human OSM
were purchased from Bio Source International. Mouse recombinant LIF was purchased
from Chemicon International. Insulin, human recombinant GH, leupeptin, chloroquine,
cycloheximide, cytochalasin B, and collagenase were all purchased from Sigma.
Epoxomicin and MG132 were purchased from Boston Biochem. U0126 was purchased
from Promega, DNase I and Trizol were purchased from Invitrogen, and PNGaseF was
purchased from New England BioLabs. All STAT antibodies were monoclonal IgGs
purchased from Transduction Laboratories or polyclonal IgGs purchased from Santa
Cruz. The highly phospho-specific polyclonal antibodies for STAT 1 (Y701), STAT 3
(Y705), and STAT 5 (Y694) were IgGs purchased from BD Transduction Laboratories and
Upstate Biotechnology, Inc. LIFR, gp130, and SREBP-1 antibodies were rabbit
polyclonal IgGs purchased from Santa Cruz. CNTFRα antibody was a mouse
monoclonal IgG purchased from BD Transduction Laboratories. PPARγ antibody was a
mouse monoclonal IgG purchased from Santa Cruz. ERK1/ERK2 antibody was a rabbit
polyclonal IgG purchased from Santa Cruz. Active ERK and active Akt (S473) antibodies
were rabbit polyclonal IgGs purchased from Cell Signaling Technology. Akt and FAS
antibodies were rabbit polyclonal IgGs purchased from BD Transduction Laboratories.
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IRS-1 antibody was a polyclonal IgG purchased from Upstate Biotechnology, Inc. The
phospho-specific IRS-1 (Y896) antibody was a polyclonal IgG purchased from Biosource
International. HRP-conjugated streptavidin used for detection of ACC was purchased
from Pierce. LPL antibody was a monoclonal IgG purchased from R & D Systems.
Acrp30 antibody was a polyclonal IgG purchased from Affinity Bioreagents.
C/EBPα antibody was a rabbit polyclonal IgG provided by the lab of Dr. Ormond
MacDougald (Ann Arbor, MI), and GLUT 4 antibody was a rabbit polyclonal IgG
provided by the lab of Dr. Paul Pilch (Boston, MA). HRP-conjugated secondary
antibodies were purchased from Jackson Immunoresearch. Enhanced
chemiluminescence (ECL) kit was purchased from Pierce. Nitrocellulose and Zeta
Probe-GT membranes were purchased from BioRad.
2.2 Cell Culture
Murine 3T3-L1 preadipocytes were plated and grown to 2 days post confluence in
DMEM with 10% bovine serum. Medium was changed every 48 hours. Cells were
induced to differentiate by changing the medium to DMEM containing 10% fetal bovine
serum, 0.5 mM 3-isobutyl-1-methylxanthine, 1 µM dexamethasone, and 1.7 µM insulin.
After 48 hours this medium was replaced with DMEM supplemented with 10% FBS, and
cells were maintained in this medium until utilized for experimentation.
2.3 Preparation of Whole Cell Extracts
Monolayers of 3T3-L1 preadipocytes or adipocytes were rinsed with phosphatebuffered saline (PBS) and then harvested in a non-denaturing buffer containing 150 mM
NaCl, 10 mM Tris, pH 7.4, 1 mM EGTA, 1 mM EDTA, 1% Triton-X 100, 0.5% Igepal
CA-630 (Nonidet P-40), 1 µM PMSF, 1 µM pepstatin, 50 trypsin inhibitory milliunits of
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aprotinin, and 10 µM leupeptin, and 2 mM sodium vanadate. Samples were extracted for
30 minutes on ice and centrifuged at 15,000 rpm at 4oC for 15 minutes. Supernatants
containing whole cell extracts were analyzed for protein content using a BCA kit (Pierce)
according to the manufacturer's instructions.
2.4 Preparation of Nuclear and Cytosolic Extracts
Cell monolayers were rinsed with PBS and then harvested in a nuclear
homogenization buffer (NHB) containing 20 mM Tris (pH 7.4), 10 mM NaCl, and 3 mM
MgCl2. Igepal CA-630 (Nonidet P-40) was added to a final concentration of 0.15%, and
cells were homogenized with 16 strokes in a Dounce homogenizer. The homogenates
were centrifuged at 1500 rpm for 5 minutes. Supernatants were saved as cytosolic extract,
and the nuclear pellets were resuspended in half the volume of NHB and were
centrifuged as before. The pellet of intact nuclei was resuspended again in half of the
original volume of NHB and centrifuged again. A small portion of the nuclei was used
for Trypan Blue staining to examine the integrity of the nuclei. The majority of the pellet
(intact nuclei) was resuspended in an extraction buffer containing 20 mM HEPES (pH
7.9), 420 mM NaCl, 1.5 mM MgCl2, 0.2 mM EDTA, and 25% glycerol. Nuclei were
extracted for 30 minutes on ice and then placed at room temperature for 10 minutes. Two
hundred units of DNase I was added to each sample, tubes were inverted and incubated
an additional 10 minutes at room temperature. Finally, the sample was subjected to
centrifugation at 15,000 rpm at 4oC for 30 minutes. Supernatants containing nuclear
extracts were analyzed for protein content, using a BCA protein assay kit (Pierce).
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2.5 SDS Polyacrylamide Gel Electrophoresis and Western Blot Analysis
Proteins were separated in 5%, 7.5%, 10 % or 12% polyacrylamide (acrylamide
from National Diagnostics) gels containing sodium dodecyl sulfate (SDS) according to
Laemmli (Laemmli, 1970) and transferred to nitrocellulose membrane in 25 mM Tris,
192 mM glycine, and 20% methanol. Following transfer, the membrane was blocked in
4% fat-free milk for 1 hour at room temperature. Results were visualized with HRPconjugated secondary antibodies and enhanced chemiluminescence.
2.6 RNA Analysis
Total RNA was isolated from cell monolayers with Trizol according to
manufacturer’s instructions with minor modifications. For Northern blot analysis, 20 µg
of total RNA was denatured in formamide and electrophoresed through a
formaldehyde/agarose gel. The RNA was transferred to Zeta Probe-GT, cross-linked,
hybridized, and washed as previously described (Stephens and Pekala, 1991). Probes
were labeled by random priming using the Klenow fragment and [α 32P] dATP.
2.7 Determination of [3H] 2-Deoxyglucose Uptake
The assay of [3H] 2-deoxyglucose uptake was performed as previously described
(Stephens and Pekala, 1991). Prior to the assay, fully differentiated 3T3-L1 adipocytes
were serum deprived for 4 hours. Uptake measurements were performed in triplicate
under conditions where hexose uptake was linear. The results were corrected for
nonspecific uptake, and absorption was determined by [3H] 2-deoxyglcuose uptake in the
presence of 5 µM cytochalasin B. Nonspecific uptake and absorption was always less
than 10% of the total uptake.
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2.8 Rodent Tissue Isolation
Animals were euthanized by cervical dislocation, and tissues were immediately
removed, and frozen in liquid nitrogen. Frozen tissues were homogenized in a buffer
containing 150 mM NaCl, 10 mM Tris, pH 7.4, 1 mM EGTA, 1 mM EDTA, 1% TritonX 100, 0.5% Igepal CA-630(Nonidet P-40), 1 µM PMSF, 1 µM pepstatin, 50 trypsin
inhibitory milliunits of aprotinin, and 10 µM leupeptin, and 2 mM sodium vanadate.
Homogenates were centrifuged for 10 minutes at 5,000 rpm to remove any debris and
insoluble material and then analyzed for protein content. Adipocyte and stromovascular
fractions were isolated from the epididymal fat pads of male C57Bl/6J mice by
collagenase digestion. Seven week old ob/+ and ob/ob mice were purchased from
Jackson Laboratories. Eight week old fa/+ and fa/fa rats were purchased from Harlan.
For DIO experiments, 3-5 week old C57Bl/6J mice were placed on a high fat/high
sucrose diet (Research Diets # 12331 - Surwit diet) or low fat/high glucose suctose diet
(Research Diets # 12329). Twelve week-old transgenic mice expressing agouti protein
under the control of the β-actin promoter, and all other C57Bl/6J mice were obtained
from a colony at the Pennington Biomedical Research Center. All animal studies were
carried out with protocols which were reviewed and approved by institutional IACUCs.
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CHAPTER 3: EFFECTS OF CNTF ON ADIPOCYTES*

3.1 Results
The sensitivity of 3T3-L1 cells to cytokine treatment was examined by treating
undifferentiated preadipocytes and fully differentiated 3T3-L1 adipocytes with an acute
treatment of 0.8 nM CNTF or 0.8 nM LIF. As shown in Figure 3.1, immunoblotting of
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Figure 3.1 The effects of acute CNTF or LIF treatment on 3T3-L1 preadipocytes
and adipocytes. Whole cell extracts were prepared from confluent undifferentiated
preadipocytes, and from fully differentiated 3T3-L1 adipocytes following a 15 min.
treatment with CNTF (0.8 nM) or LIF (0.8 nM). Whole cell extracts were prepared and
75 µg of each extract was separated by SDS-PAGE, transferred to nitrocellulose, and
subjected to Western blot analysis.
* published as J. Biol. Chem. 278, 2228-2235, with permission from JBC.
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whole cell extracts demonstrated that both preadipocytes and adipocytes express STAT 3.
Treatment of both preadipocytes and adipocytes with LIF or CNTF resulted in the rapid
activation of STAT 3, as evident by increased tyrosine phosphorylation. However,
treatment of preadipocytes resulted in a greater stimulation of STAT 3 activation, relative
to adipocytes, despite equivalent expression of STAT 3 protein. In addition, CNTF and
LIF treatment caused a robust activation of Akt in preadipocytes, whereas the same
treatment of adipocytes did not result in a detectable activation of Akt. The expression of
two CNTF receptor complex proteins, LIFR and gp130, was also examined. LIFR was
expressed at a substantially higher level in preadipocytes than in adipocytes, whereas the
expression of gp130 protein was not different in these two cell types.
The expression of CNTF receptor complex proteins was also examined during a
time course of adipocyte differentiation. As shown in Figure 3.2A, the expression of
CNTFRα protein decreases notably after 15 minutes of induction of differentiation and
this lower level of expression is maintained for 48 hours. However, there were no
detectable levels of CNTFRα 72 hours after the initiation of differentiation in whole cell
extracts. Yet, we did observe the presence of CNTFRα at lower levels in the media up to
72 hours (Figure 3.2B). As indicated in Figure 3.1, the expression of LIFR decreased
during adipogenesis and there was a slight modulation of gp130 expression. The
expression of STAT 5A is known to be induced during adipocyte differentiation and is
shown as a positive control for adipogenesis.
Since the expression of two CNTF receptor complex proteins was reduced during
adipogenesis, we wanted to determine whether these proteins were expressed in adipose
tissue, and to compare the expression levels to other tissues. Whole cell extracts were
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Figure 3.2. The expression of CNTF receptor complex proteins during adipocyte
differentiation. Whole cell extracts and media samples were prepared from 3T3-L1 cells
at various times following the induction of differentiation. Cells were induced to
differentiate at 2 days post confluence with the addition of a differentiation cocktail
containing 10% FBS, 0.5 mM 3-isobutyl-1-methylxantine, 1.0 µM dexamethasone, and
1.7 µM insulin. After 48 hours this medium was replaced with DMEM supplemented
with 10% FBS, and cells were maintained in this medium until utilized for
experimentation. In each panel, 100 µg of corresponding extract was separated by SDSPAGE, transferred to nitrocellulose, and subjected to Western blot analysis.

isolated from the various tissues indicated in Figure 3.3. Western blot analysis revealed
lung, stomach, epididymal fat, spleen, heart, brain, testes, and skeletal muscle as tissues
expressing both CNTFRα and LIFR. All of these tissues had comparable receptor
expression levels, except for the brain, which had significantly higher levels of CNTFRα
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expression. Also, the molecular weight of CNTFRα in stomach and brain was greater
than in other tissues. In agreement with our earlier observations (Figure 3.2), the
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Figure 3.3 Tissue distribution of CNTF receptor complex components in rodents.
Tissue extracts were prepared from eight-week old Sprague-Dawley rats. Seventy five µg
of each extract was separated by SDS-PAGE, transferred to nitrocellulose, and subjected
to Western blot analysis. Whole cell extracts from 3T3-L1 preadipocytes and adipocytes,
as well as tissue extracts from the epididymal fat pads from lean and obese Zucker rats,
were also examined by Western blot analysis as positive controls.
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expression of CNTFRα was abundant in preadipocytes and undetectable in 3T3-L1
adipocytes. We also observed that the expression of CNTFRα was upregulated in the
epididymal fat pad of an obese Zucker rat as compared to a lean littermate.
To determine if the altered mobility of CNTFRα was due to glycosylation, tissue
extracts were incubated with PNGaseF. As shown in Figure 3.4, treatment with PNGaseF
resulted in deglycosylation of CNTFRα and LIFR. In particular, the CNTFRα bands of
larger molecular weights (brain and stomach) co-migrated with the CNTFRα from other
tissues following digestion, indicating that the size difference between CNTFRα in these
tissues was due to different glycosylation patterns. Also, all LIFR bands migrated at the
same molecular weight following PNGaseF treatment.
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Figure 3.4 Glycosylation of CNTF receptor complex components in rat tissues.
Tissue extracts were prepared from eight-week old Sprague-Dawley rats. Eighty µg of
each extract was incubated with 4 µL of PNGaseF (5,000 U/µl) as directed by the
manufacturer’s instruction and then separated by SDS-PAGE, transferred to
nitrocellulose, and subjected to Western blot analysis.
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Although our results demonstrate that fully differentiated 3T3-L1 adipocytes do
not express CNTFRα, it has previously been demonstrated that CNTF can signal via
gp130 and LIFR in the absence of CNTFRα (Gearing et al., 1994; Monville et al., 2001).
Therefore, we examined the ability of CNTF to activate STATs in a time dependent
manner in 3T3-L1 adipocytes. Serum-deprived fully differentiated 3T3-L1 adipocytes
were harvested at the times indicated in Figure 3.5 and fractionated into cytosolic and
nuclear extracts. As shown in Figure 3.5A, CNTF administration to 3T3-L1 adipocytes
resulted in the nuclear translocation of STAT 3. STAT 3 was present in the nucleus after
a 10 or 30 minute treatment with CNTF and the amount of STAT 3 nuclear protein was
decreased after a 1 hour treatment. After 2 hours, there was little STAT 3 present in the
nucleus. CNTF treatment did not result in the activation/nuclear translocation of STAT 1
or STAT 5B, indicating the specificity of the response. Also, CNTF did not effect the
distribution of STAT 5A. Unlike other adipocyte expressed STATs, some STAT 5A is
always present in the adipocyte nucleus (Balhoff and Stephens, 1998). The dose
dependent effects of CNTF on 3T3-L1 adipocytes were also examined by treating
adipocytes for 10 minutes with varying concentrations of CNTF. As shown in Figure
3.5B, CNTF had no effect on STATs 1 or 5A, but resulted in the tyrosine
phosphorylation and nuclear translocation of STAT 3. In addition, CNTF treatment
resulted in a dose dependent activation of MAPK (ERKs 1 and 2). To assess the dose
effects of CNTF on STAT 3 activation, we compared STAT 3 activation in preadipocytes
and adipocytes. As shown in Figure 3.5C, CNTF results in a dose dependent effect on
STAT 3 activation in preadipocytes, but not in adipocytes.
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Figure 3.5 Time and dose dependent effects of CNTF administration on the
phosphorylation and nuclear translocation of STAT proteins in 3T3-L1 cells.
Cytosolic and nuclear extracts were prepared from fully differentiated 3T3-L1 adipocytes
following a treatment with (A) 0.8 nM CNTF for the times indicated, or after (B) 10 min.
CTNF treatment at the doses indicated. (C) Whole cell extracts were prepared from both
preadipocytes and from fully differentiated 3T3-L1 adipocytes following a 10 min.
treatment with CNTF at the doses shown in the figure. Seventy five µg of each extract
was separated by SDS-PAGE, transferred to nitrocellulose, and subjected to Western blot
analysis.
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To further characterize the effects of CNTF, fully differentiated 3T3-L1
adipocytes were treated for a 12 hour period. As shown in Figure 3.6, acute CNTF
treatment resulted in a time dependent activation of STAT 3 and MAPK, but was unable
to activate Akt. A positive control for Akt activation (10 min. treatment of 3T3-L1
adipocytes with 50 nM insulin) is shown in the bottom panel of the figure. Acute CNTF
treatment did not affect the expression levels of STATs 1, 3, and 5A, or the 67 kDa
active form of SREBP-1.
Next, we examined the effects of chronic CNTF administration on the expression
of adipocyte transcription factors and other adipocyte proteins. Fully differentiated 3T3L1 adipocytes were exposed to CNTF over a 96 hour period. A fresh bolus of CNTF was
added to the cells every 24 hours. Whole cell extracts were isolated at the times indicated
in Figure 3.7 and subjected to Western blot analysis. Chronic administration of CNTF
did not alter the expression of adipocyte expressed STATs, PPARγ, or C/EBPα. Also,
there were no notable differences in the levels of gp130 and LIFR expression, and
chronic CNTF treatment was insufficient to induce the expression of CNTFRα. A
positive control of confluent preadipocytes is shown for CNTFRα expression. We also
observed that CNTF treatment did not alter the expression of Acrp 30 in 3T3-L1
adipocytes. Moreover, CNTF had no effect on the expression or secretion of leptin from
3T3-L1 adipocytes (data not shown). Interestingly, CNTF treatment resulted in a
decrease of fatty acid synthase (FAS) expression and a substantial increase in the
expression of IRS-1. Also, the levels of the 67 kDa SREBP-1 protein were slightly
decreased by CNTF treatment after 72 hours.
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Figure 3.6 The effects of acute CNTF administration on the expression of adipocyte
proteins. Whole cell extracts were prepared from fully differentiated 3T3-L1 adipocytes
treated with 0.8 nM CNTF for the times shown. Seventy five µg of each extract was
separated by SDS-PAGE, transferred to nitrocellulose, and subjected to Western blot
analysis.
Although we did not observe substantial levels of CNTFRα in cultured 3T3-L1
adipocytes (Figures 3.2, 3.3, and 3.5), we were able to detect the expression of CNTFRα
in rodent adipose tissue from an obese Zucker rat and the levels of this receptor appeared
to be up regulated in conditions of obesity (Figure 3.3). Hence, we examined the
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Figure 3.7 The effects of chronic CNTF administration on the expression of
adipocyte proteins. Whole cell extracts were prepared from fully differentiated 3T3-L1
adipocytes treated with 0.8 nM CNTF for the times indicated at the top of the figure.
Seventy five µg of each extract was separated by SDS-PAGE, transferred to
nitrocellulose, and subjected to Western blot analysis.
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expression of CNTF receptors in adipose tissue of additional rodent models of
obesity/type 2 diabetes. Whole cell extracts were prepared from epididymal fat pads of
five ob/ob and five ob/+ lean littermates. As shown in Figure 3.8A, we observed very
little expression of CNTFRα in the adipose tissue of lean mice, but observed a substantial
increase in the expression of this receptor in three of the five obese insulin resistant ob/ob
littermates. In the other two ob/ob mice, there was a modest increase in CNTFRα
expression. In addition, we observed increased LIFR expression in all five ob/ob mice
compared to lean littermates, but did not observe any substantial changes in gp130
expression. We also examined the expression of these proteins in the epididymal fat pads
of fa/+ and fa/fa rats. As shown in Figure 3.8B, the expression of CNTFRα was also
substantially up regulated in this rodent model of obesity/type 2 diabetes. However, we
did not observe an increase in LIFR levels in the fa/fa rats as compared to their lean
littermates, although there was a modest increase in gp130 levels in adipose tissue from
fa/fa rats. We also examined the expression of these receptors in transgenic mice that
over express agouti under the control of the β-actin promoter, a condition which causes
obesity and type 2 diabetes (Klebig et al., 1995). As shown in Figure 3.8C we observed a
substantial increase in CNTFRα levels in the epididymal fat pads of three obese
transgenic mice (Tg/+) compared to wild type lean (+/+) mice. There was also a modest
decrease in LIFR and gp130 in the fat pads of mice with agouti-induced obesity. Finally,
we examined the expression of CNTF receptors after low fat or high fat feeding in
C57B1/6J mice. Seven mice from each condition were analyzed for CNTF receptor
expression. The results in Figure 3.8D only include three animals per condition.
However, this pattern of regulation was observed for all seven animals examined
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Figure 3.8 The expression of CNTF receptor components in the adipose tissue of
lean and obese rodents. Whole cell extracts were isolated from the epididymal fat pads
of (A) seven-week old ob/+ (lean) and ob/ob (obese) littermate mice, (B) eight-week old
fa/+ (lean) and fa/fa (obese) littermate rats, (C) twelve-week old lean mice or obese
agouti (Tg/+) littermates, and (D) seventeen-week old C57B1/6J mice fed a low or high
fat diet for twelve weeks. In each panel, 75 µg of each extract was separated by SDSPAGE, transferred to nitrocellulose, and subjected to Western blot analysis.
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for each condition (data not shown). In C57B1/6J mice, we observed an increase in
CNTFRα levels with high fat feeding after twelve weeks. A similar pattern was also
observed after seven weeks (data not shown). Overall, there was no modulation of LIFR
or gp130 with high fat feeding in the C57B1/6J mice.
We have shown that cultured adipocytes do not express CNTFRα, but rodent
adipose tissue expresses detectable levels of the receptor. Therefore, we examined the
ability of CNTF to activate STAT 3 in vivo. C57B1/6J mice were given an intraperitoneal
injection of CNTF (33.3 µg/kg) or vehicle (saline) control. Fifteen minutes after the
injection, the mice were sacrificed and epididymal adipose tissue, brains, and skeletal
muscle were immediately removed and frozen in liquid nitrogen. Whole cell extracts
were prepared from these tissues and analyzed for STAT 3 phosphorylation by Western
blot analysis. As shown in Figure 3.9A, acute CNTF treatment resulted in the activation
of STAT 3 in epididymal adipose tissue. We were unable to detect STAT 3
phosphorylation in the adipose tissue of five saline injected mice, but four of the five
CNTF injected mice had readily detectable levels of phosphorylated STAT 3. The
increase in STAT 3 phosphorylation was not due to increased STAT 3 expression. Also,
the expression of LIFR was not changed and the levels of CNTFRα were variable in the
ten mice. The results in Figure 3.9B demonstrate constitutive STAT 3 phosphorylation in
brain, which was unresponsive to exogenous CNTF. Moreover, we observed an increase
in STAT 3 phosphorylation in the skeletal muscle of CNTF treated animals, as compared
to saline controls. As previously indicated (Figure 3.3), the levels of CNTFRα in the
brain are substantially greater than the levels in skeletal muscle.

49

A
92 kDa

STAT 3 Tyr705

92 kDa

STAT 3

180 kDa

LIFR

60 kDa

CNTFRα
saline

CNTF

epididymal fat pads

B
92 kDa

STAT 3 Tyr705

92 kDa

STAT 3

180 kDa

LIFR

60 kDa

CNTFRα
saline

CNTF

saline

brain

CNTF

skeletal muscle

Figure 3.9 In vivo effect of acute CNTF administration in rodents. Six-week old
male C57B1/6J mice were given an intraperitoneal injection of CNTF (33.3 µg/kg) or
vehicle (saline) control. Fifteen minutes after the injection the mice were sacrificed and
epididymal fat pads, brains, and skeletal muscle were immediately removed and frozen in
liquid nitrogen. Tissue extracts were analyzed from (A) epididymal fat pads and (B) brain
and skeletal muscle. In each panel, 75 µg of each extract was separated by SDS-PAGE,
transferred to nitrocellulose, and subjected to Western blot analysis.
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Figure 3.10 In vivo expression of CNTFRα in epididymal fat pads. Epididymal fat
pads were extracted from six-week old lean C57B1/6J mice and fractionated into
adipocyte and stromovascular fractions. Seventy five µg of each extract was separated
by SDS-PAGE, transferred to nitrocellulose, and subjected to Western blot analysis.

Our results demonstrate that CNTFRα receptor expression was decreased during
the adipogenesis of 3T3-L1 cells, but expressed in the fat pads of rodents. Therefore, we
fractionated epididymal fat pads from C57B1/6J mice to determine if the CNTFRα
receptor was expressed in the stromovascular fraction or in the adipocytes. As shown in
Figure 3.10, our results clearly demonstrate that CNTFRα is expressed highly in the
adipocytes whereas STAT 3 is expressed at higher levels in the stromovascular portion.
We hypothesize that the loss of CNTFRα that occurs during differentiation in vitro
(Figure 3.2A) could be an artifact of cell culture since this receptor is expressed in native
adipocytes (Figure 3.10) and in media obtained from cultured 3T3-L1 adipocytes (Figure
3.2B).
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Figure 3.11 CNTF does not cause insulin resistance, but increases GLUT 4
expression. (A) Whole cell extracts were prepared from fully differentiated 3T3-L1
adipocytes treated with 0.8 nM CNTF for the times shown. Seventy five µg of each
extract was separated by SDS-PAGE, transferred to nitrocellulose, and subjected to
Western blot analysis. (B) Fully differentiated 3T3-L1 adipocytes were treated with
CNTF for 72 hours. A fresh bolus of CNTF was added to the cells very 24 hours.
Monolayers of adipocytes were used to examine glucose uptake as indicated in the
Experimental Procedures.
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Figure 3.12 The effects of acute CNTF treatment on IRS-1 and Akt activation in
3T3-L1 adipocytes. Whole cell extracts were prepared from fully differentiated 3T3-L1
adipocytes treated with 0.8 nM CNTF or 50 nM insulin for the times indicated in the
figure. Seventy five µg of each extract was separated by SDS-PAGE, transferred to
nitrocellulose, and subjected to Western blot analysis.

In light of the reports that CNTF administration to ob/ob, db/db, and DIO mice
has been shown to improve insulin sensitivity in vivo, we examined the ability of CNTF
to regulate insulin sensitive glucose uptake in 3T3-L1 adipocytes. Fully differentiated
3T3-L1 adipocytes were treated for 24 hours with CNTF. As shown in Figure 3.11A,

53

CNTF treatment resulted in a notable increase (25-50%) in GLUT 4 levels. However,
additional treatments of CNTF did not result in a further increase in GLUT 4 levels as
chronic CNTF treatment did not substantially increase GLUT 4 mRNA or protein levels
(data not shown). Therefore, we examined the ability of CNTF to affect glucose uptake.
Fully differentiated adipocytes were treated for 72 hours with CNTF. Every 24 hours,
cells were treated with a fresh bolus of CNTF. Acute insulin treatment (50 nM, 7 min.)
resulted in a five-fold increase in insulin-stimulated glucose uptake and was relatively
unaffected by chronic CNTF treatment (Figure 3.11B). In addition, CNTF had no effect
on basal glucose uptake.
Since CNTF treatment resulted in an increase in IRS-1 expression levels (Figure
3.7), we examined the ability of this cytokine to induce IRS-1 activation, as judged by
tyrosine phosphorylation at residue 896. As shown in Figure 3.12, acute insulin treatment
(15 min.) results in the activation of IRS-1 and Akt, whereas acute CNTF treatment does
not. However, CNTF pretreatment (30 min.) prior to insulin stimulation resulted in an
increased IRS-1 activation (>20%) and increased Akt phosphorylation (>25%). The
efficacy of the CNTF is demonstrated by the activation of STAT 3.
3.2 Discussion
In the light of recent findings demonstrating that CNTF administration results in
weight loss and correction of many other obesity/type 2 diabetes related symptoms
(Gloaguen et al., 1997; Henderson et al., 1996; Lambert et al., 2001; ALS CNTF
Treatment Study Group, 1996), we hypothesized that the effects of this cytokine may not
be limited to the CNS, and that CNTF may also have effects on peripheral tissues such as
adipose tissue. Our in vitro studies using 3T3-L1 preadipocytes and adipocytes have
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shown that CNTF indeed has significant, yet different, effects on these two cell types. In
3T3-L1 adipocytes we observed that CNTF was a potent activator of the Jak/STAT
pathway, in particular STAT 3, as well as an activator of a MAPK signaling cascade that
resulted in activation of ERKs 1 and 2. In preadipocytes CNTF elicited similar effects but
also resulted in the activation of Akt. Our studies revealed that two of the three CNTF
receptor components, LIFR and CNTFRα, were down regulated during the adipogenesis
of 3T3-L1 cells. Our study clearly demonstrates that the expression of CNTFRα is
substantially decreased during the course of adipocyte differentiation. Other studies have
shown that CNTFRα is down regulated during astrocyte differentiation (Monville et al.,
2001). A previous investigation had also indicated a decrease in LIFR during
adipogenesis (Aubert et al., 1999b), but this is the first investigation to demonstrate a
decrease in CNTFRα during adipogenesis. We hypothesize that decreased expression of
CNTF receptors upon differentiation accounts for cultured adipocytes being less sensitive
to CNTF treatment than preadipocytes, as judged by STAT 3 or Akt activation.
Although LIFR and CNTFRα protein levels are reduced in cultured adipocytes, as
compared to preadipocytes, we observed that adipocytes were still responsive to CNTF. It
has been previously demonstrated that CNTF can induce signaling in the absence of
CNTFRα, solely by binding to a gp130:LIFR dimeric receptor (Gearing et al., 1994;
Monville et al., 2001). Acute treatment of CNTF did not alter the expression levels of
any STATs or any other adipocyte transcription factors in 3T3-L1 adipocytes. Hence, we
examined the chronic effects of CNTF on 3T3-L1 adipocytes and observed that this
cytokine affected the expression of several adipocyte-enriched proteins; including
SREBP-1, FAS, GLUT4, and IRS-1. The reduction in the levels of SREBP-1 and FAS is
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indicative of decreased biosynthesis of fatty acids that may account for some portion of
weight loss and decreased fat mass observed in patients treated with CNTF (Axokine). In
agreement with previous finding that this CNTF-induced weight loss was not due to
cachexia or inflammation (Lambert et al., 2001; Pu et al., 2000), we did not observe any
effect of CNTF on PPARγ or C/EBPα, two transcription factors known to be down
regulated by inflammatory cytokines such as TNFα and IFNγ (Ganoth et al., 2001;
Tanaka et al., 1999; Waite et al., 2001). Also, unlike the in vitro effects of other
cytokines (Stephens et al., 1992; Stephens et al., 1993; Bastard et al., 2002; Waite et al.,
2001), CNTF treatment of 3T3-L1 adipocytes did not result in the onset of insulin
resistance (Figure 3.11). Moreover, chronic CNTF treatment of these cells actually
resulted in an increase in both GLUT4 and IRS-1 protein levels. However, we did not
observe any effects of CNTF on basal or insulin-stimulated glucose uptake. Clearly,
additional experiments are required to determine if CNTF can act as an insulin sensitizer.
Nonetheless, we have shown that CNTF appears to act synergistically with insulin to
increase the level of IRS-1 and Akt phosphorylation in 3T3-L1 adipocytes.
Our results strongly suggest that CNTF affects adipose tissue and skeletal muscle
in vivo since an acute intraperitoneal injection of CNTF resulted in STAT 3 activation in
both tissues. We also observed that CNTFRα is expressed not only in brain and skeletal
muscle, but also in adipose tissue, spleen, heart, testes, lungs and stomach. The receptor
expression levels, as well as the protein size, vary among these tissues, but our
deglycosylation studies clearly demonstrate that they all express CNTFRα. One of the
most important findings we observed was that, in vivo, CNTFRα expression was
significantly increased in four different rodent models of obesity/type 2 diabetes,
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including both genetic and diet-induced obesity. Moreover, we have shown that
CNTFRα is expressed at higher levels in the adipocytes as compared to the
stromovascular portion of the fat pad (Figure 3.10). Although we observed an increase in
the expression of the LIFR in the ob/ob mice, as compared to lean littermates, the
expression of this receptor was not altered in the fa/fa rats or in C57Bl/6J mice with dietinduced obesity.
The results of our study suggest that CNTF and CNTFRα may play a role in the
regulation of adipocyte metabolism and, perhaps, the control of adipose tissue mass. Our
results have led us to hypothesize that CNTF can act as an insulin sensitizer in
adipocytes. Therefore, the up regulation of CNTFRα in adipose tissue of obese/type II
diabetic rodents could be an adaptive response attempting to increase insulin sensitivity.
Interestingly, some studies suggest that CNTFRα may not only act as receptor for CNTF,
but also as a receptor for another unknown CNTF-like factor. For example, mice lacking
CNTF develop normally and appear to have no visible defects well into adulthood, when
they develop minor loss of motor neurons (Masu et al., 1993). Yet, mice lacking
CNTFRα tend to have severe motor neuron defects and die perinatally because they fail
to initiate feeding behaviors (DeChiara et al., 1995). Also, the finding that CNTF
expression is undetectable in the feeding-relevant brain sites, that express high levels of
CNTFRα (Gloaguen et al., 1997), further supports the notion that CNTFRα may have
additional ligands and/or functions.
In summary, we observed that native as well as cultured adipocytes are responsive
to CNTF treatment. Interestingly, CNTFRα is not highly expressed in cultured
adipocytes, but readily detectable in rodent adipose tissue and furthermore highly up
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regulated in multiple rodent models of obesity/type 2 diabetes. This is the first
demonstration that this receptor is expressed in adipose tissue and that it is highly
regulated in obesity/type 2 diabetes. Current studies are underway to determine the role
of CNTFRα in adipose tissue function and examine the ability of CNTF to act as insulin
sensitizer in fat and muscle.
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CHAPTER 4: EFFECTS OF CT-1 ON ADIPOCYTES

4.1 Results
In order to examine the sensitivity of 3T3-L1 cells to CT-1 administration,
confluent 3T3-L1 preadipocytes and fully differentiated 3T3-L1 adipocytes were treated
with CT-1 (0.20nM) for the times indicated in Figure 4.1. Western blot analysis of cell
extracts revealed that both undifferentiated and differentiated 3T3-L1 cells responded to
CT-1 treatment in a time dependent manner.
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Figure 4.1 The effects of acute CT-1 treatment on 3T3-L1 preadipocytes and
adipocytes. Whole cell extracts were prepared from confluent undifferentiated
preadipocytes, and from fully differentiated 3T3-L1 adipocytes following a treatment
with 0.2 nM CT-1 for the times indicated. One hundred and twenty five µg of each
extract was separated by SDS-PAGE, transferred to nitrocellulose, and subjected to
Western blot analysis.
Exposure to CT-1 resulted in a time dependent activation and tyrosine phosphorylation of
STATs 1 and 3, as well as activation of MAPK (ERKs 1 and 2). The magnitudes of the
responses were undistinguishable in undifferentiated and differentiated 3T3-L1 cells.
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However, the tyrosine phosphorylation of STAT 3 was sustained for a longer period of
time in preadipocytes. The total levels of MAPK are shown as a control for even loading.
The subcellular distribution of STAT proteins following CT-1 treatment was
assessed by treating fully differentiated 3T3-L1 adipocytes with CT-1 (0.20nM) for
various periods of time, followed by isolation of cytosolic and nuclear extracts. Western
blot analysis of these extracts, shown in Figure 4.2, clearly demonstrated that CT-1
treatment results in the nuclear translocation of STATs 1, 3, 5A, and 5B, as well as the
activation of MAPK.
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Figure 4.2 The effects of acute CT-1 treatment on the activation and nuclear
translocation of STAT proteins in 3T3-L1 adipocytes. Cytosolic and nuclear extracts
were prepared from fully differentiated 3T3-L1 adipocytes following a treatment with 0.2
nM CT-1 for the times indicated. One hundred µg of each extract was separated by SDSPAGE, transferred to nitrocellulose, and subjected to Western blot analysis.
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For each STAT protein examined, nuclear translocation occurred within 15 minutes and
returned to basal level within 2 hours following the cytokine treatment. This pattern is
consistent with STAT activation by CNTF (Zvonic et al., 2003a) and other gp130
cytokines in 3T3-L1 adipocytes.
To further examine the ability of CT-1 to activate STATs in 3T3-L1 adipocytes in
comparison to other gp130 cytokines, we exposed fully differentiated adipocytes to
various doses of CT-1, CNTF, and LIF for 15 minutes.
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Figure 4.3 Dose dependent effects of CT-1 on 3T3-L1 adipocytes. Whole cell extracts
were prepared from fully differentiated 3T3-L1 adipocytes following a 15 min. treatment
with CT-1, CNTF, or LIF, with the doses indicated in the figure. One hundred and fifty
µg of each extract was separated by SDS-PAGE, transferred to nitrocellulose, and
subjected to Western blot analysis.
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Western blot analysis of whole cell extracts, shown in Figure 4.3, indicated that the
activation of STATs 1, 3, and 5, and MAPK (ERKs 1 and 2) by CT-1 is dose dependent.
Moreover, the STAT 3 activation was achieved at much lower doses of CT-1 than those
required for activation of STAT 1 and STAT 5. As previously shown CNTF does not
activate STAT 3 in a dose dependent manner (Zvonic et al., 2003a). CNTF treatment
also did not result in either STAT 1 or STAT 5 activation. Treatment with 2.0 nM CNTF
resulted in substantially less STAT 3 and MAPK activation when compared to 2.0 nM
CT-1. LIF treatment also resulted in a dose dependent activation of STATs 1, 3, and 5,
and MAPK, in a manner and dose comparable to that of CT-1. The total levels of MAPK
are shown as a control for even loading.
To characterize in vivo effects of CT-1 on native adipocytes, seven-week old
C57B1/6J mice were given an intraperitoneal injection of CT-1 (0.5µg/animal) or vehicle
(saline) control and sacrificed after 15 minutes. Western blot analysis of whole cell
extracts isolated from the epididymal fat pads of the animals, shown in Figure 4.4,
demonstrated that the four mice injected with CT-1 had a significant increase in levels of
active MAPK and tyrosine phosphorylated STATs 1 and 3. There was no detectable
STAT activation in the four saline injected mice, although some active MAPK was
observed. Interestingly, the activation of STAT 5 by CT-1 was not observed in this
experiment. The total levels of MAPK are shown as a control for even loading, while an
extract from 3T3-L1 adipocytes treated with GH was used as a positive control for STAT
5 activation (Zvonic et al., 2003b).
To assess the effect of chronic CT-1 treatment on 3T3-L1 adipocytes, fully
differentiated adipocytes were exposed to CT-1 over a time course of 96 hours. A fresh
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Figure 4.4 In vivo effect of acute CT-1 administration in rodents. Seven-week old
male C57B1/6J mice were given an intraperitoneal injection of 0.1 nM CT-1 (0.5
µg/animal) or vehicle (saline) control. Fifteen minutes after the injection the mice were
sacrificed and epididymal fat pads were immediately removed and frozen in liquid
nitrogen. One hundred and fifty µg of each tissue extract was separated by SDS-PAGE,
transferred to nitrocellulose, and subjected to Western blot analysis.
bolus of CT-1 was added to the cells every 24 hours. As shown in Figure 4.5, chronic
administration of CT-1 resulted in decreased protein levels of FAS and IRS-1 after 72
and 96 hours of treatment. The levels of ACC, the 67 kDa form of SREBP-1, and Akt
were unchanged. In addition, there were no significant effects on the levels of STATs 1,
3, and 5A. Interestingly, CT-1 administration resulted in a transient downregulation of
PPARγ protein following a 24 hour CT-1 treatment. However, after 48 hours, PPARγ
levels had returned to basal levels and additional CT-1 treatments did not result in
decreased PPARγ following chronic (48-96 hrs) CT-1 treatment.

63

260 kDa

ACC

260 kDa

FAS

170 kDa

IRS-1

91 kDa

STAT 1

92 kDa

STAT 3

95 kDa

STAT 5A

67 kDa

SREBP-1

60 kDa

Akt

40 kDa

PPARγ
CTL
24
start

CTL
48 72 96 end hrs of CT-1

Figure 4.5 The effects of chronic CT-1 administration on the expression of
adipocyte proteins. Whole cell extracts were prepared from fully differentiated 3T3-L1
adipocytes following a treatment with 0.2 nM CT-1 for the times shown. One hundred µg
of each extract was separated by SDS-PAGE, transferred to nitrocellulose, and subjected
to Western blot analysis.

The differentiation of 3T3-L1 preadipocytes into mature adipocytes is governed
by a variety of cell signals. To determine whether CT-1 signaling can affect adipocyte
differentiation we exposed differentiating preadipocytes to CT-1, as well as CNTF. Either
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cytokine was added to the culture at the time of the induction of differentiation, and the
cells were maintained in the presence of the cytokine for the entire course of
differentiation. Whole cell extracts were collected at the various time points indicated in
Figure 4.6, and were analyzed by Western blotting. Our results demonstrate that the
treatment with neither CT-1 nor CNTF had any profound effects on adipocyte
differentiation, as evident by the unaltered expression levels of various adipocyte markers
such as PPARγ, IRS-1, STAT 5A, and ACC. Interestingly, the presence of CT-1 during
3T3-L1 differentiation resulted in a notable decrease in FAS expression. CNTF also had a
modest effect on FAS expression. The presence of these cytokines did not effect the
expression of their shared receptor complex proteins, LIFR and gp130, nor did it affect
the expression levels of their downstream kinases, such as Akt and ERKs 1 and 2. The
expression of PPARγ and STAT 5A are known to be induced during adipocyte
differentiation and serve as obvious markers of successful adipogenesis.
Since CT-1 did not affect the adipogenesis of 3T3-L1 cells, we examined the
effects of this cytokine on the expression of genes in fully differentiated 3T3-L1
adipocytes. Since this cytokine is a potent STAT activator, both in vitro and in vivo
(Figure 4.2 and Figure 4.4), we hypothesized that activated STATs would induce a
transcriptional modulation of their target genes. Serum deprived, fully differentiated 3T3L1 adipocytes were treated with CT-1 (0.20nM) or CNTF (0.45nM) for various times, as
indicated in Figure 4.7. Total RNA and whole cell extracts were collected following the
treatment. As shown in Figure 4.7A, both CT-1 and CNTF administration resulted in a
rapid induction of SOCS-3 mRNA levels. However, this upregulation is very transient
following CNTF treatment, while CT-1 treatment, at a dose lower than that of CNTF,
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Figure 4.6 The effects of CT-1 and CNTF treatment on the differentiation of 3T3L1 adipocytes. Whole cell extracts were prepared from 3T3-L1 cells at various times
following the induction of differentiation. Cells were induced to differentiate as described
in Figure 3.2. A fresh bolus of CT-1 (0.2 nM) or CNTF (0.45 nM) was added to the cells
every 24 hours during the course of differentiation. One hundred µg of each extract was
separated by SDS-PAGE, transferred to nitrocellulose, and subjected to Western blot
analysis.
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Figure 4.7 The effects of acute CT-1 and CNTF administration on the expression of
adipocyte proteins. Total RNA (A and C) or whole cell extracts (B) were isolated from
fully differentiated 3T3-L1 adipocytes following a treatment with CT-1 (0.2 nM), CNTF
(0.45 nM), or U0126 (5.0 µM) for the times shown. Twenty µg of each total RNA was
electrophoresed, transferred to nylon, and subjected to Northern blot analysis. One
hundred µg of each whole cell extract was separated by SDS-PAGE, transferred to
nitrocellulose, and subjected to Western blot analysis.
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resulted in a more sustained induction of SOCS-3 mRNA. Both cytokines also resulted
in a transient downregulation of PPARγ mRNA, which was more evident following a 2
hour CT-1 treatment. The levels of aP2 mRNA were unchanged. The efficacy of the
cytokines in this experiment was demonstrated by their ability to induce STAT 3
phosphorylation (Figure 4.7B). In order to determine whether the repression of PPARγ
mRNA or induction of SOCS-3 mRNA induced by CT-1 was mediated through the ERK
MAP kinase pathway, 3T3-L1 adipocytes were pretreated with U0126, a MEK inhibitor.
The Northern blot analysis in Figure 4.7C clearly demonstrates that both SOCS-3 mRNA
upregulation and PPARγ mRNA downregulation are not dependent on the activity of
ERKs 1 and 2, because the addition of U0126 failed to prevent modulation of mRNA
levels by CT-1.
4.2 Discussion
Cardiotrophin (CT-1) is a newly identified member of the gp130 cytokine family
that signals via a receptor complex comprised of gp130 and LIFR signal transducer
proteins. Recent work from our laboratory has shown that another member of the gp130
cytokine family, CNTF, can activate several signaling pathways and regulate protein
expression levels in 3T3-L1 adipocytes (Zvonic et al., 2003a). These effects are likely to
be induced by utilizing only gp130 and LIFR as signal transducers, since the specific
CNTF receptor, CNTFRα, is not expressed in fully differentiated 3T3-L1 adipocytes
(Figure 3.2A). Since, both IL-6 and CNTF have effects on body weight regulation
(Henderson et al., 1996; Bastard et al., 2002), we have investigated the actions of CT-1 in
vitro and in vivo to determine if this gp130 cytokine can induce similar signaling effects
in fat cells, and regulate adipocyte gene expression.
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Our results demonstrated that administration of CT-1 to both preadipocytes and
3T3-L1 adipocytes resulted in similar downstream responses. Interestingly, and in
contrast to CNTF, CT-1 activated STATs 1 and 3, as well as ERKs 1 and 2 MAP kinases
in both cell types, and the responses were of identical magnitudes, but slightly more
sustained in preadipocytes. Since the levels of gp130 remain fairly unaffected by
differentiation, and LIFR is expressed by mature adipocytes, both cell types have a
significant population of these receptors on their cell surfaces. Therefore, both are likely
activated by CT-1, and these cells are responsive to the administration of this cytokine.
The attenuation of the response duration in adipocytes, as compared to preadipocytes,
could be attributed to the slight loss of LIFR expression that occurs during adipocyte
differentiation (Aubert et al., 1999a).
Further investigation of CT-1 actions in adipocytes showed that CT-1 was also
capable of activating STATs 5A and 5B, in addition to STATs 1 and 3. STATs 5A and
5B in 3T3-L1 adipocytes were not activated by CNTF or other gp130 cytokines. Hence,
their activation by CT-1 presents a rather novel finding and may, upon further
investigation, prove to be a mechanism for the specificity of this cytokine's action. The
activation of these proteins was confirmed through their detection in the nuclear fraction
from the cells following cytokine treatment. STAT proteins translocated to the nucleus
within 15 min after the treatment, and were mostly gone within 2 h. These are parameters
consistent with STAT activation by other cytokines in adipocytes (Stephens et al., 1998).
These data also indicate that STATs activated by CT-1 are not only tyrosine
phosphorylated, but also move into the nucleus where they can act as transcription
factors.
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Since CNTF has not been shown to activate adipocyte STAT 3 and ERKs 1 and 2
in a dose dependent manner, we treated adipocytes with a range of CT-1 doses. Unlike
CNTF, CT-1 was capable of activating STATs 1, 3, and 5, as well as ERKs 1 and 2, in a
dose dependent manner. Activation of these proteins by CT-1 also occurred at much
lower doses, and with higher magnitude of activation, if compared to that of CNTF. Once
again, we hypothesize that this response is due to the abundance of gp130 and LIFR in
adipocytes. Unlike CNTF, which has a limited affinity for gp130/LIFR dimer in the
absence of CNTFRα, CT-1 is not limited by the absence of the cytokine-specific receptor
component and can bind gp130/LIFR dimer with a very high affinity (Pennica et al.,
1995b). LIF, a gp130 cytokine which also utilizes the gp130/LIFR dimer to transduce its
signals, is capable of activating an identical profile of adipocyte STATs as CT-1, and also
does so in a dose dependent manner. Thus, taking into account the results discussed so
far, one can hypothesize that the availability of receptor component proteins can
significantly affect the magnitude, duration, variety, specificity, and dose dependency of
a cytokine response in a given cell type.
Since native adipocytes also express both gp130 and LIFR proteins, we
investigated the in vivo effect of CT-1 administration on adipose tissue of C57B1/6J
mice. Shortly after injection, CT-1 was able to activate STATs 1 and 3, as well as ERKs
1 and 2, in the epididymal fat pads of these animals, mimicking the in vitro effect in 3T3L1 adipocytes. However, the dose administered (0.1 nM) was not sufficient to induce the
activation of STAT 5. This is consistent with the dose dependency results from the in
vitro studies. Even though further studies will be necessary to determine if CT-1 can
activate STAT 5 at higher doses in vivo, it is still quite exciting to discover that this
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cytokine directly affects fat tissue, and may potentially have biological roles in native
adipocyte function.
In light of our results from the acute CT-1 administration, we also examined the
effects of chronic CT-1 treatment in 3T3-L1 adipocytes. Upon 96 hours of treatment, CT1 resulted in a decrease of FAS and IRS-1 protein levels. CNTF had an identical effect on
FAS but an opposite effect on IRS-1 (Figure 3.7). The levels of STATs, Akt, and
SREBP-1 remained constant throughout the treatment, unlike that of PPARγ. CT-1 first
induced a transient decrease in the protein levels, consistent with the decrease in mRNA
levels we observed in the acute treatment. However, PPARγ protein expression was then
transiently upregulated before returning to the basal level. The potential ability of CT-1
to regulate PPARγ could prove to be interesting in relation to its effects on adipocytes.
More importantly, the downregulation of IRS-1 expression by CT-1 could be a possible
marker of impaired insulin sensitivity of these cells. Therefore, further work should be
done to address this finding. Even though there are no reports of upregulated circulating
levels of CT-1 in conditions of insulin resistance, this modulation of insulin resistance by
CT-1 can serve as a model to study the effect of elevated circulating levels of CT-1 in the
serum of patients with ischemic heart disease and valvular heart disease (Freed et al.,
2003). Clinical aspects of these diseases are tightly linked to obesity/type 2 diabetes
(Reaven et al., 2004; Sowers and Frohlich, 2004), while the principal cause of diabetes
mortality is cardiovascular disease (CVD) (Nesto, 2003). Therefore, CT-1 may act as a
link between obesity-related complications and CVD.
Adipocyte differentiation is marked by changes in the expression of several
adipocyte-specific proteins. Since CT-1 and CNTF both activate the JAK/STAT pathway
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in 3T3-L1 cells, we examined the ability of these cytokines to regulate adipogenesis.
Unlike TNFα or IFNγ, the presence of CT-1 or CNTF did not inhibit adipocyte
differentiation. These studies suggest that the anti-obesity effects of CNTF are not
mediated by inhibiting fat cell differentiation. Interestingly, both cytokines induced a
decrease in the expression of FAS, which we have achieved previously by a chronic
CNTF treatment in adipocytes (Figure 3.7). However, the expression of ACC, a rate
limiting enzyme in fatty acid synthesis was not affected by the treatment. Since CT-1
administration did not affect lipid accumulation (data not shown), we can not be certain
whether CT-1 could potentially affect lipid biosynthesis in adipocytes. There was no
evident change in the expression levels of LIFR, gp130, STATs, MAPK (ERKs 1 and 2),
IRS-1, or Akt, indicating that neither of these cytokines regulate the expression of
proteins involved in their own signaling and their further downstream actions. Most
importantly, the expression of PPARγ, a key marker of adipogenesis, increased during the
course of differentiation, and was not affected by either cytokine.
Although CT-1 and CNTF did not affect adipocyte differentiation, we further
investigated the acute effects of these cytokines on fully differentiated 3T3-L1
adipocytes. Acute treatment of 3T3-L1 adipocytes with CNTF and CT-1 resulted in a
significant induction of SOCS-3 mRNA levels. Within an hour, the levels returned to
base line in the CNTF treated cells, but remained elevated even after 8 hours in CT-1
treated adipocytes. However, this data was not very surprising due to the fact that SOCS3 mRNA levels are regulated by activated STATs (Brender et al., 2001), and we have
shown that the activation of STATs by CT-1, especially the activation of STAT 3, is
temporally prolonged, compared to that induced by CNTF. Another interesting finding is
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that both cytokines, especially CT-1, resulted in a transient decrease of PPARγ mRNA
levels. This result may be related to the transient decrease in the PPARγ protein observed
during the chronic administration (Figure 4.5). Previous studies (Tanaka et al., 1999),
including one from our laboratory (Waite et al., 2001), have already shown that STATs
activated by various cytokines regulate PPARγ mRNA levels. Since CT-1 is
predominantly known for its roles as an activator of the JAK/STAT and MAPK
pathways, we were interested in determining which of these pathways was involved in
the induction of SOCS-3 and the attenuation of PPARγ mRNA levels. When MAPK
pathway was inhibited by a specific MEK inhibitor U0126, we still observed a rise in
SOCS-3 and a decrease in PPARγ mRNA levels upon CT-1 treatment. Hence, our
studies suggest that the MAPK pathway is not involved in CT-1 induced regulation of
SOCS-3 and PPARγ mRNA levels. Because the previous work from our lab has also
shown that STAT 1 activated by IFNγ downregulates the expression of PPARγ via the 221 to -207 site within the promoter (Hogan and Stephens, 2001), it would be interesting
to investigate the ability of STAT 1 activated by CT-1 to bind this promoter element.
In summary, we have observed that CT-1 acts as a potent activator of both
JAK/STAT and MAPK pathways in both preadipocytes and 3T3-L1 adipocytes, as well
as in rodent fat pads in vivo. Unlike CNTF, CT-1 activation of these pathways is more
robust, dose dependent, and sustained. This is also the first report of STAT 5 activation
by a gp130 cytokine in 3T3-L1 adipocytes. Even though neither CNTF nor CT-1 had any
significant effects on adipocyte differentiation, both cytokines induced transient changes
in SOCS-3 and PPARγ mRNA and protein levels in adipocytes, which mirrored the
ability of the individual cytokine to activate the JAK/STAT pathway. Since other gp130
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cytokines have been implied as potential mediators of various aspects of obesity/type 2
diabetes, it would be interesting to further investigate the actions of CT-1 in this arena.
However, the strongest focus should be placed on elucidating the actions of elevated
levels of circulating CT-1 during obesity-related CVD, and the effects of this cytokine on
adipose tissue in patients suffering from obesity/type 2 diabetes.
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CHAPTER 5: CROSS-TALK AMONG GP130 CYTOKINES IN
ADIPOCYTES
5.1 Results
One of the unifying features of all gp130 cytokines is their ability to activate
JAK/STAT and MAPK (ERKs 1 and 2) signaling pathways. We therefore wanted to
determine if gp130 cytokines can work synergistically to initiate these signals, or if their
actions antagonize each other. In order to answer this question, we pretreated fully
differentiated 3T3-L1 adipocytes with various gp130 cytokines for 2 hours, and then
treated them for 15 minutes with either 0.2 nM CT-1, 0.45 nM CNTF, 0.1 nM LIF, or GH
(125 ng/mL). As shown in Figure 5.1, gp130 cytokines primarily interacted in an
antagonistic fashion. Results in Figure 5.1A demonstrate that the ability of CT-1 to
activate either the JAK/STAT or the MAPK pathway can be impaired by pretreatment
with several different gp130 cytokines. Consistent with our previous data (Figure 4.1),
CT-1 treatment resulted in a robust activation of STAT 1 and STAT 3. However, a 2
hour pretreatment with LIF, OSM, or CT-1 completely blocked STAT 1 activation
induced by a 15 minute CT-1 treatment. These same cytokines also interfered with the
activation of STAT 3 by CT-1. In this case, LIF acted as the most potent inhibitor, while
CT-1 and OSM only partially blocked the effects of acute CT-1 treatment. No
appreciable STAT 5 activation occurred with CT-1 treatment, while GH pretreatment
caused a robust STAT 5 activation detectable even at the end of experiment. The ability
of LIF, OSM, and CT-1 to block further actions of CT-1 was also evident through their
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Figure 5.1 gp130 cytokine administration affects cell signaling of their family
members. Fully differentiated 3T3-L1 adipocytes were preincubated with either IL-6 (2
ng/mL), LIF (0.1 nM), OSM (0.5 ng/mL), GH (125 ng/mL), CNTF (0.45 nM), or CT-1
(0.2 nM) for 2 hours. The cells were then treated for 15 min. with either (A) CT-1, (B)
CNTF, (C) LIF, or (D) GH. Following the treatment, whole cell extracts were prepared,
and 150 µg of each extract was separated by SDS-PAGE, transferred to nitrocellulose,
and subjected to Western blot analysis.
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effects on MAPK (ERKs 1 and 2) signaling, since the activation of this pathway by
chronic CT-1 administration was attenuated by pretreatment with these cytokines.
Even though CNTF is not a potent activator of JAK/STAT or MAPK signaling in
adipocytes (Figure 3.5), its ability to activate STAT 3 (Figure 5.1B) was affected by the
pretreatment with other gp130 cytokines. As was the case with the chronic CT-1
treatment, 2 hour pretreatment of adipocytes with either LIF, OSM, or CT-1 significantly
decreased the magnitude of STAT 3 activation by CNTF. These effects were not
observed in relation to MAPK due to the fact that, in this experiment, CNTF failed to
activate this pathway.
Data in Figure 5.1C recapitulates the fact that, in adipocytes, LIF acts as a potent
activator of JAK/STAT and MAPK signaling. Still, its actions as a STAT 1 and STAT 5
activator were completely abolished by the 2 hour preincubation of adipocytes with LIF,
OSM, or CT-1. An identical pattern of inhibition was also observed with the activation
of MAPK (ERKs 1 and 2) by a 15 minute LIF treatment. In this experiment, acute LIF
administration resulted in an extremely robust STAT 3 activation, and only the 2 hour
pretreatment with LIF resulted in its slight attenuation.
Acute treatment with GH, shown in Figure 5.1D, also lead to a robust induction of
JAK/STAT and MAPK signaling, as evident by the activation of STATs 1, 3, and 5, and
ERKs 1 and 2. However, unlike the gp130 cytokines, the ability of GH to activate these
pathways was not affected by a 2 hour preincubation with any of the gp130 cytokines. In
fact, LIF, OSM, and CT-1 seemed to work synergistically with GH when activating
STAT 3. The only inhibitory effect observed was the inhibition of GH by a 2 hour
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preincubation with GH itself. STAT 5A levels were shown in all panels of Figure 5.1 as
controls for even loading.
In order to confirm these findings, we used a similar experimental approach in an
in vivo model. C57B1/6J mice were injected with 0.05 nM CT-1 or the appropriate
vehicle control, then injected again 4 hours later, and finally sacrificed 15 minutes
following the second round of injections. As shown in Figure 5.2, intraperitoneal
administration of CT-1 lead to the activation of STAT 3 in the mouse epididymal fat
pads. Interestingly, MAPK (ERKs 1 and 2) appeared to be active even in animals
injected with vehicle (saline) control. As expected, phosphorylated proteins were present
in the cell extracts 15 minutes after the injection. We were also able to detect active
STAT 3 and MAPK even 4 hours following CT-1 administration, at a level comparable
to that of a 15 minute treatment. However, the animals injected with CT-1 for 4 hours,
and then again for 15 minutes, showed no change in STAT 3 or MAPK activation, as
compared to animals injected with CT-1 for either length of treatment. Total MAPK
levels are shown as an even loading control.
Another common feature of gp130 cytokines is their shared use of gp130 and
LIFR proteins as signal transducers within their receptor complexes. Therefore, we
examined the effect of gp130 cytokine signaling on these proteins. As shown in Figure
5.3A, the expression level of LIFR in 3T3-L1 adipocytes dramatically decreases within 6
hours in the absence of de novo protein synthesis (achieved through incubation with
cycloheximide). Addition of LIF, a ligand for LIFR, further accelerates this degradation
process, to where a significant decrease in LIFR levels is apparent within 1 hour of the
treatment, and no protein is detectable after 4 hours. Addition of a proteasome inhibitor,
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Figure 5.2 CT-1 pretreatment in vivo blocks acute CT-1 signaling in rodent fat
pads. Six-week old male C57B1/6J mice were given an intraperitoneal injection of 0.05
nM CT-1 (0.25 µg/animal) or vehicle (saline) control. Four hours later the animals were
injected again. Fifteen minutes after the second injection the mice were sacrificed and
epididymal fat pads were immediately removed and frozen in liquid nitrogen. One
hundred and fifty µg of each tissue extract was separated by SDS-PAGE, transferred to
nitrocellulose, and subjected to Western blot analysis.

MG132, failed to prevent the loss of LIFR protein, nor did it have an effect on
accelerated protein loss following LIF treatment. However, the addition of leupeptin and
chloroquine, which together act as a lysosome inhibitor, prevented the degradation of
LIFR under basal conditions, or after LIF treatment.
These findings were recapitulated by the experiment shown in Figure 5.3B. In
this case, we used a highly specific proteasome inhibitor, epoxomicin, in lieu of MG132.
The data shown clearly indicate that the loss of LIFR induced by 6 hour incubation with
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Figure 5.3 Administration of LIF alters the half-life of LIFR protein in adipocytes.
(A) Fully differentiated 3T3-L1 adipocytes were treated with either 0.1 nM LIF, 20 µM
MG132, a mixture of 200 µM chloroquine and 10 µM leupeptin (L/C), or a combination
of LIF and the inhibitors. The treatments were done in the presence of 5 µM
cycloheximide (CH). Whole cell extracts were prepared from treated adipocytes at the
times indicated. (B) Whole cell extracts were prepared from fully differentiated 3T3-L1
adipocytes treated for 6 hours with either 0.1 nM LIF, 100 nM epoxomicin (EPX), L/C,
or a combination of LIF and the inhibitors, in the presence of CH. In each panel, 150 µg
of extract was separated by SDS-PAGE, transferred to nitrocellulose, and subjected to
Western blot analysis.
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Figure 5.4 Half-life of LIFR is altered by gp130 cytokine administration. Whole cell
extracts were prepared from 3T3-L1 adipocytes treated with either LIF (0.1 nM), CT-1
(0.2 nM), CNTF (0.45 nM), OSM (0.5 ng/mL), IL-6 (2 ng/mL), or GH (125 ng/mL) for 4
hours in the presence of 5 µM cycloheximide (CH), or a mixture of CH and 200 µM
chloroquine and 10 µM leupeptin (L/C). One hundred µg of each sample was separated
by SDS-PAGE, transferred to nitrocellulose, and subjected to Western blot analysis.

cycloheximide was not affected by epoxomicin, but was prevented with a combination of
leupeptin and chloroquine. Furthermore, these effects were mirrored by the ability of
leupeptin and chloroquine to prevent the complete loss of LIFR induced by LIF
treatment. Epoxomicin was unable to generate the same effect. Total MAPK (ERKs 1
and 2) levels are also shown as a control for even loading.
In order to explain why LIF, CT-1 and OSM seemed to have prominent inhibitory
effects on gp130 cytokine signaling, we examined the ability of all gp130 cytokines
toaffect the expression levels of LIFR protein in 3T3-L1 adipocytes. As shown in Figure
5.4, 4 hour incubation with cycloheximide induced a notable decrease in LIFR levels.
However, addition of LIF, CT-1, or OSM to these cells resulted in a complete or, in case
of OSM, nearly complete loss of LIFR expression. Interestingly enough, the addition of
CNTF, IL-6, or GH did not induce a decrease in LIFR levels greater than the decrease
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induced by cycloheximide. Consistent with the data from Figure 5.3, the loss of LIFR
expression through the action of cycloheximide alone, or with LIF, CT-1, and OSM, was
blocked by the addition of leupeptin and chloroquine to the cell media. Total MAPK
(ERKs 1 and 2) levels are shown as controls for even loading.
5.2 Discussion
Synchronous functional redundancy and specificity is likely the most interesting
attribute of gp130 cytokine biology (Paul, 1989; Kishimoto et al., 1992). Even though
the specific mechanisms governing the actions of these cytokines are still unknown, there
is a general consensus regarding several aspects of gp130 cytokine signaling. As their
name suggests, all members of the gp130 cytokine family use gp130 protein as a transmembrane signal transducer within their functional receptor complexes (Taga et al.,
1992; Taga, 1996). The presence of gp130 is crucial for the recruitment of other receptor
complex components (Savino et al., 1994), and for the propagation of signal to the
downstream targets, such as the components of the JAK/STAT or MAPK pathways
(Narazaki et al., 1994; Lutticken et al., 1994). Several gp130 cytokines (LIF, OSM,
CNTF, CT-1) also use LIFR as a part of their functional receptor complexes (Gearing et
al., 1991; Gearing et al., 1992; Ip et al., 1992; Davis et al., 1993b; Pennica et al., 1995b).
Both gp130 and LIFR are expressed in vivo as well as in cultured adipocytes (Aubert et
al., 1999c; Zvonic et al., 2003a), and several studies have shown that various gp130
cytokines have the ability to induce intracellular signaling in these cell types (Path et al.,
2001; Metcalf, 2003; Zvonic et al., 2003a).
The question posed by the findings in the above mentioned studies is whether
gp130 cytokines can act synergistically to activate their downstream targets, or whether

84

their actions antagonize the individual cytokine’s ability to induce signaling. The results
from our studies are a strong argument for the latter scenario. CT-1, LIF, and OSM
demonstrated the ability to attenuate or, in some cases, completely abolish subsequent
signaling by their family members. CNTF or IL-6 did not seem to have the same effect.
However, the inhibitory effects of CT-1, LIF, and OSM were not observed with GH
treatment, while GH was only able to interfere with its own signaling. This finding
suggests that the attenuation of gp130 cytokine signaling does not occur at the level of
intracellular signal transducers. Is this were the case, then GH signaling would have been
affected as well, since this growth factor propagates its signal through the JAK/STAT and
MAPK pathways in a manner similar to gp130 cytokines (Dinerstein-Cali et al., 2000).
Interestingly, the results from our in vivo study were quite consistent with our findings.
In this case, CT-1 was able to block subsequent CT-1induction of STAT 3 activation.
However, unlike in 3T3-L1 adipocytes, STAT 3 activation by CT-1 was sustained
throughout the pretreatment period. However, no additional STAT 3 activation occurred
after subsequent CT-1 injections, demonstrating the inhibitory effect of the pretreatment.
Nonetheless, due to the limited scope of this study, we were not able to demonstrate
whether the inhibition occurred at the receptor or at the cytoplasmic signaling level.
Since the experiments in cultured adipocytes pointed at a possible inhibition of
signaling at the level of the receptor, we examined the effects of gp130 cytokines on the
stability and availability of LIFR. Previous studies (Blanchard et al., 2001) have shown
that gp130 cytokine signaling affects the turnover and degradation of LIFR while having
no effect on gp130. Consistent with these findings, we have shown that the half-life of
LIFR is dramatically shortened by LIF administration. We have also demonstrated that,
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in 3T3-L1 adipocytes, basal or ligand-induced degradation of LIFR can be prevented by
the addition of lysosomal inhibitors leupeptin and chloroquine. Proteasome inhibitors
MG132 or epoxomicin did not alter the half-life of LIFR under basal conditions or
following LIF administration.
To further investigate the effects of gp130 cytokines on LIFR stability, we treated
3T3-L1 adipocytes with these cytokines and analyzed the levels of LIFR following the
treatment. Aside from LIF, both CT-1 and OSM also had profound effects on the
degradation of LIFR. All of these cytokines use LIFR as a component of their receptor
complexes, and therefore induce its endocytosis and degradation (Blanchard et al., 2000).
The effect of CNTF was marginal, while IL-6 and GH had no effect on LIFR levels. IL-6
signals via the complex of gp130 and IL-6Rα, and therefore does not affect LIFR, while
the receptor for GH shares no common components with gp130 cytokine receptor
complexes. CNTF signals through the receptor complex of gp130, LIFR, and CNTFRα.
However, differentiated 3T3-L1 adipocytes do not express CNTFRα (Zvonic et al.,
2003a), so the ability of this cytokine to form functional receptor complexes, and induce
LIFR degradation, is severely impaired. In agreement with the previous experiment,
inhibition of the lysosome with leupeptin and chloroquine completely prevented the loss
of LIFR.
In summary, a striking parallel has emerged during this study, linking the ability
of a given cytokine to block subsequent cytokine signaling and its ability to induce LIFR
degradation. Namely CT-1, LIF, and OSM, three cytokines with the strongest inhibitory
effects on signaling, were also the most potent inducers of LIFR degradation. Therefore,
we hypothesize that the ability to block the signaling of gp130 cytokines is closely tied to
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their ability to induce LIFR degradation, making it unavailable for the formation of
receptor complexes to propagate further signaling. Conversely, CNTF, IL-6, and GH did
not affect the turnover of the LIFR and therefore did not block the signaling abilities of
other cytokines. Needless to say, several other studies will be necessary to elucidate the
exact fate of LIFR following cytokine treatment, namely whether lysosomal inhibition
prevents endocytosis of LIFR, as well as its degradation. In this case, lysosomal
inhibitors could potentially reverse the ability of CT-1, LIF, and OSM to inhibit cytokine
signaling, because LIFR would remain available for further signaling events.
However, these findings do serve as a base for future studies of cytokine
interactions, which could be used to mimic various disease states marked by
simultaneous expression of several cytokines (Kamimura et al., 2003), or to create novel
approaches in inducing the differentiation of various progenitor cell lines (Gimble et al.,
1994). Most importantly, this system may be used to describe the signaling events in
adipocytes under the influence of macrophages. Two recent studies (Weisberg et al.,
2003; Xu et al., 2003) have demonstrated that macrophage accumulation in adipose
tissue, and subsequent secretion of cytokines by these macrophages, could possibly be
some of the initial events leading to the onset of obesity and type 2 diabetes.
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CHAPTER 6: SUMMARY AND CONCLUSIONS

6.1 Summary
Signaling of gp130 cytokines in various cell types has been extensively studied
during the last decade. Studies of this system have lead to numerous important
discoveries that impact our understanding of cell biology and physiology. Previous work
on gp130 cytokine actions in adipocytes has shown that certain members of this family,
such as IL-6 (Bastard et al., 2002) or LIF (Tanaka et al., 1999), have the ability to
dramatically alter the physiology of fat, and consequently impact the overall function of
the body.
Our studies with CNTF have demonstrated several interesting functions of this
cytokine in adipocytes. Apart from being able to activate JAK/STAT (STAT 3) and
MAPK (ERKs 1 and 2) signaling, both in vitro and in vivo, CNTF was capable of
modulating the expression of SREBP-1, FAS, GLUT4, and IRS-1 protein levels.
Administration of CNTF to 3T3-L1 adipocytes also increased the ability of insulin to
activate its downstream targets IRS-1 and Akt. However, this cytokine did not alter the
ability of insulin to stimulate the uptake of glucose by adipocytes in vitro.
Another novel finding of our study is that the expression of the cytokine-specific
receptor for CNTF, CNTFRα, is lost during the differentiation of 3T3-L1 adipocytes.
However, we have shown that CNTFRα is expressed in rodent fat pads in vivo. Our
study has also demonstrated the expression of CNTFRα in other rodent tissues such as
lung, stomach, skeletal muscle, spleen, heart, pancreas, brain, testes, and kidneys.
Interestingly, these tissues expressed not only different quantities of CNTFRα, but also
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different forms of the protein. Subsequently, we were able to show that the variation in
CNTFRα size was due to different glycosylation patterns of the protein. However, the
most interesting finding in this study was that the expression of CNTFRα in rodent fat
pads is substantially increased under the conditions of obesity/type 2 diabetes. This was
the case in all three genetic and one diet-induced models of obesity we examined.
Therefore, we hypothesize that CNTF may act as an insulin sensitizer in insulin-resistant
fat pads in vivo, under the conditions of obesity/type 2 diabetes.
We followed up our CNTF studies by testing the ability of CT-1 to affect 3T3-L1
adipocytes in a similar fashion. CT-1 treatment was able to initiate JAK/STAT and
MAPK (ERKs 1 and 2) signaling, both in vitro and in vivo. However, the activation
pattern induced by CT-1 occurred in a dose-dependent manner, and was much more
robust and sustained, closely resembling LIF signaling. Also, unlike CNTF which
activated only STAT 3, CT-1 administration lead to the activation and nuclear
translocation of STATs 1, 3, 5A, and 5B. Chronic treatment of 3T3-L1 adipocytes with
CT-1 resulted in downregulation of FAS and IRS-1 protein levels, as well as a transient
decrease in PPARγ protein expression. Just like CNTF, CT-1 had no significant effects
on the expression levels of adipocyte proteins during the time course of fat cell
differentiation. However, both cytokines induced the upregulation of SOCS-3 mRNA in
3T3-L1 adipocytes shortly after their administration. Consistent with its potent activation
of the JAK/STAT and MAPK pathways, CT-1 generated a much more robust and
sustained increase in SOCS-3 mRNA, when compared to CNTF. Both cytokines also
caused a transient decrease in PPARγ mRNA levels, resembling the transient effect on its
protein levels. When administered in the presence of a MEK inhibitor U0126, CT-1 was
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still capable of modulating both the SOCS-3 and PPARγ mRNA expression, indicating
that MAPK pathway is not required for this cytokine-induced regulation of gene
expression. Even though our study of CT-1 actions in adipocytes is still under way, we
hypothesize that this cytokine may act to modulate acute PPARγ expression, and can also
affect insulin signaling, due to its ability to decrease the expression of IRS-1.
We also tested the ability of gp130 cytokines to interact with signaling of their
family members. The results of our study indicate that CT-1, LIF, and OSM have
interfered with the ability of gp130 cytokines to induce phosphorylation of various
STATs and ERKs 1 and 2. However, since the signaling of GH was not affected by
gp130 cytokines, we hypothesized that the inhibition occurs at the level of the receptor,
and not the cytosolic signal transducers. Therefore, we examined the ability of gp130
cytokines to alter the half-life of shared receptor proteins. The half-life of gp130 protein
is not affected by cytokine binding (Blanchard et al., 2000), so we focused on LIFR. Our
results demonstrate that cytokine binding dramatically shortened the half-life of LIFR
protein, and that the degradation of LIFR can be prevented by the addition of lysosome
inhibitors leupeptin and chloroquine, but not by proteasome inhibitors MG132 or
epoxomicin. Within the gp130 cytokine family, CT-1, LIF, and OSM were capable of
inducing LIFR degradation. These were the same cytokines capable of inhibiting
signaling of their family members. Hence, even though strictly based on correlative data,
we hypothesize the cytokine-induced loss of LIFR makes this protein unavailable for the
formation of functional receptor complexes upon further cytokine stimulation, and
therefore plays an important part in the mechanism of gp130 cytokine-induced signaling
inhibition.
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6.2 Conclusions
A serendipitous finding that CNTF may induce weight loss and improve insulin
sensitivity in obese/diabetic patients (ALS CNTF Treatment Study Group, 1996) has
implicated gp130 cytokines as possible therapeutic agents for the treatment of these
diseases. Even though the mechanism of CNTF action in this scenario has not yet been
elucidated, and the clinical trials have faced serious problems, we now know that the
members of the gp130 cytokine family have the ability to substantially affect adipose
physiology.
The ability of CNTF to activate JAK/STAT and MAPK signaling in adipocytes,
and to regulate the expression of several proteins involved in adipocyte function (FAS,
IRS-1, GLUT4, SREBP-1), suggests that the actions of this cytokine in adipose may
contribute to the overall amelioration of obesity/type 2 diabetes-related complications by
the CNTF treatment. This notion is further supported by our finding that, in adipocytes,
CNTF acts to enhance insulin signaling at the level of IRS-1 and Akt activation. The
increased expression of CNTFRα in obese/diabetic rodents suggests that a ligand for this
receptor may act to reverse the symptoms of these diseases. Since recent studies
(DeChiara et al., 1995) have demonstrated CNTF is not the preferred ligand for
CNTFRα, the cloning of a specific (or production of a synthetic) ligand for this receptor
may prove to be a much more effective obesity/type 2 diabetes treatment.
Even though CT-1 is primarily known for its roles in cardiomyocyte physiology,
we have demonstrated the ability of CT-1 to activate STAT 5 and modulate the
expression of PPARγ mRNA in adipocytes. Since the activity of PPARγ and STAT 5 is
very important for adipocyte differentiation (Tontonoz et al., 1994; Chawla et al., 1994;
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Floyd and Stephens, 2003), CT-1 may prove to be capable of regulating this process. Of
most interest, however, is the downregulation of IRS-1 expression by CT-1, which can
possibly lead to the onset of insulin resistance. As previously indicated (Freed et al.,
2003), circulating levels of CT-1 are increased in the serum of patients with ischemic
heart disease and valvular heart disease. Since the clinical aspects of these diseases are
tightly linked to obesity/type 2 diabetes (Reaven et al., 2004; Sowers and Frohlich,
2004), CT-1 may prove to be a link between obesity-related complications and CVD,
such as hypertension or atherosclerosis. To this day, the principal cause of diabetes
mortality is cardiovascular disease (CVD) (Nesto, 2003).
The potential of cross-talk among gp130 cytokines is also of utmost interest. As
we have shown in our studies, several gp130 cytokines have the ability to attenuate the
actions of other family members, by altering the availability of receptor complex
components. Therefore, this approach could be used to develop combination therapies,
where one cytokine could be used to “prime” the cell for the action of another. Hence,
some of the detrimental side-effects of a given therapeutic cytokine could be attenuated
by pretreating the patient. Since various disease states are marked by the elevation in one
or more cytokines (Kamimura et al., 2003), gp130 cytokine interaction system can be
used to model such events for further study. The differentiation of progenitor cell lines
into terminally differentiated cell types can also be governed by gp130 cytokines (Gimble
et al., 1994). Hence, our understanding of the interactions among these factors may be
applied toward optimizing the differentiation potential and efficiency of various
progenitor cell lines. Two recent studies (Weisberg et al., 2003; Xu et al., 2003) have
also demonstrated that macrophage accumulation in adipose tissue, and subsequent
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simultaneous secretion of multiple cytokines by these macrophages, could possibly be the
initial events leading to the onset of obesity and type 2 diabetes. Therefore, understanding
how cytokines, alone and in combination with others, affect the function of adipocytes,
will be crucial in elucidating the mechanism by which macrophage accumulation in fat
leads to obesity and type 2 diabetes symptoms.
Understanding the physiology of adipose tissue, as well as its functions in the
onset of various disease states, is becoming increasingly important in our quest to
develop a strategy to combat the deadly epidemic of obesity and type 2 diabetes. The
results from our studies clearly indicate that gp130 cytokines exhibit a wide spectrum of
actions in adipocytes, both in vitro and in vivo. Therefore, we believe that continued
research of gp130 cytokine actions in adipocytes will prove useful in the development of
novel approaches to study adipose physiology and obesity-associated diseases.
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